Trehalose- and Glucose-Derived Glycoamphiphiles: Small-Molecule and Nanoparticle Toll-Like Receptor 4 (TLR4) Modulators by Rodríguez Lavado, Julio et al.
 1 
Trehalose- and glucose-derived glycoamphiphiles: 
small-molecule and nanoparticle Toll-like Receptor 
4 (TLR4) modulators 
Julio Rodriguez Lavado,
†
 Stefania E. Sestito,
‡
  Roberto Cighetti,
‡
 Eva M. Aguilar Moncayo,
† 
Alja 
Oblak,
§
 Duško Lainšček, § José Luis Jiménez Blanco,† José Manuel García Fernández, ¶ Carmen 
Ortiz Mellet,
 †
 Roman Jerala,
 §
 Valentina Calabrese,
 ‡
 Francesco Peri*
, ‡
 
†
 Department of Organic Chemistry, Faculty of Chemistry, University of Sevilla, E-41012 
Sevilla, Spain. 
‡
Department of Biotechnology and Biosciences, University of Milano Bicocca; Piazza della 
Scienza, 2; 20126 Milano, Italy. 
§ 
National Institute of Chemistry, Dept. of Biotechnology; Hajdrihova 19; SI-1001 Ljubljana and 
EN-FIST center of excellence, SI-1000, Ljubljana, Slovenia. 
¶
Instituto de Investigaciones Químicas (IIQ), CSIC - Univ. Sevilla, E-41092 Sevilla, Spain. 
KEYWORDS: TLR4, MD-2, CD14, lipid A, LPS, trehalose, glucose, glycolipids, medicinal 
chemistry, drug development, gold nanoparticles, HEK cells, in vivo activity. 
ABSTRACT. An increasing number of pathologies have been linked to Toll-like Receptor 4 
(TLR4) activation and signaling. New hit and lead compounds that target the TLR4 activation 
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process are urgently needed. We report on the synthesis and biological properties of protonatable 
glycolipids based on glucose and trehalose scaffolds. Some of these compounds potently inhibit 
TLR4 activation and signaling in cells transfected with human and mouse variants of TLR4, 
MD-2 and CD14 receptors and are active in inhibiting TLR4-dependent cytokine production in 
vivo. Structure-activity relationship studies indicate that the presence of fatty ester chains in the 
molecule is a primary prerequisite for biological activity in this family of compounds and points 
to facial amphiphilicity as a preferred architecture for TLR4 antagonist design. Experimental 
data also support that single molecules, and not micellar aggregates, are the active species.  
Because the cationic glycolipids here presented exhibit negligible toxicity at their active 
concentrations, they can be cosidered as new lead compounds for the development of drugs 
targeting TLR4 activation and signaling in infectious, inflammatory and autoimmune diseases. 
Interestingly, the biological activity of the best drug candidate was retained after adsorption at 
the surface of colloidal gold nanoparticles, broadening the options for clinical development. 
INTRODUCTION 
Toll-like receptors (TLRs) play a critical role in the recognition of conserved pathogen-
associated molecular patterns (PAMPs) derived from various microbial pathogens including 
viruses, bacteria, protozoa and fungi, and in the subsequent initiation of innate immune 
response.
1
 Among TLRs, TLR4 selectively responds to bacterial endotoxin (E), composed by 
bacterial lipopolysaccharides (LPS) or part of it (lipooligosaccharides, LOS, lipid A).
2, 3
 LPS is 
the main chemical component of the Gram negative bacteria outer membrane, and the lipid A, a 
negatively charged phosphorylated lipodisaccharide represents the LPS moiety that is 
responsible for TLR4 activation through specific molecular recognition processes (Figure 1). 
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TLR4 is also activated by endogenous molecules, generally known as danger-associated 
molecular patterns (DAMPs).
4
 Typical DAMPs acting as TLR4 agonists are released as a 
consequence of injury and inflammation. Most of the reported DAMPs, are proteins, which are 
very different from lipid A, and the molecular details of DAMP interaction with the TLR4 
receptorial system are still unknown, although in some cases endotoxin contamination seems to 
be responsible for TLR4 activity of DAMPs. Chemical entities that block TLR4 activation by 
bacterial endotoxin (LPS) thus acting as antagonists, are hit compounds for developing drugs 
active against acute sepsis and septic shock derived from excessive and deregulated TLR4 
activation and signaling.
5
 On the other hand, the inhibition of TLR4 stimulation by DAMPs 
could be used to contrast a wide range of inflammatory and autoimmune disorders associated to 
the release of inflammatory cytokines. In this context, TLR4 is an emerging molecular target 
related to an impressively broad spectrum of modern day disorders including autoimmune 
disorders, chronic inflammations, allergies, asthma, atherosclerosis, aortic aneurysm, CNS 
diseases such as neuropathic pain, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease 
(AD), and some types of cancer.
6
 As the majority of these pathologies still lack specific 
pharmacological treatment, small molecules active in inhibiting TLR4 activation have attracted 
increasing interest in a wide range of possible clinical settings.
7
  
The molecular mechanism by which endotoxin activate TLR4 is a complex process
8
 and depends 
on LPS binding protein (LBP)
9
-catalyzed extraction and transfer of individual LPS molecules 
from aggregated LPS to the CD14 (cluster of differentiation 14) receptor,
10
 and then from CD14 
to myeloid differentiation protein 2 (MD-2).
11, 12
 This process is followed by engagement and 
dimerization of TLR4 thus forming the cell surface complex (LPS
.
MD-2
.
TLR4)2,
13
 which 
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initiates the intracellular signaling by recruiting specific adaptor proteins and activating 
downstream signaling pathways.  
Several natural and synthetic small molecules are known to modulate TLR4 activation and 
subsequent intracellular signaling acting as agonists (activators) or antagonists (inhibitors).
6
 The 
majority of these molecules are lipid A variants and synthetic lipid A mimetics that reproduce 
the structural motif of the anionic disaccharide. Monophosphoryl lipid A (MPL) and some 
aminoalkyl glucosaminide phosphates (AGPs) are agonists in use as vaccine adjuvants,
14
 while 
underacylated variants such as natural lipid IVa
15
 and synthetic Eritoran
®16
 are antagonists 
(Figure 1). In general Lipid A variants are anionic lipids, bearing one or two negatively charged 
phosphate groups and a hydrophobic domain (lipid chains). Although counterintuitive, several 
cationic lipids made of positively charged headgroups (usually tertiary or quaternary ammonium 
salts or polyamines) and a hydrophobic domain (alkyl chains or steroids) have been found to be 
active in modulating TLR4 activity,
17
 acting either as agonists or antagonists of TLR4. Thus, 
some positively charged liposomes formed by cationic amphiphiles induce the expression of pro-
inflammatory mediators. For instance, diC14-amidine (Figure 1) liposomes trigger the secretion 
of a cytokine pattern reminiscent of the TLR4-dependent LPS secretion pattern by activating 
both MyD88/NF-B/JNK and TRAM/TRIF pathways.18 Other cationic lipids activate cytokine 
production through NF-B-independent, TRIF-dependent pathways, which requires the presence 
of CD14.
19, 20
 Structural changes make cationic lipids switch from agonism to antagonism, as in 
the case of dioleoyl trimethylammonium propane (DOTAP), that inhibits TLR4 signal by 
competing with LPS for interaction with LBP or/and CD14.
20
 Complexes of the commercial 
cationic lipid formulation Lipofectamine
®
 with LPS reduce its TLR4 activity. Interestingly LPS 
complexed with Lipofectamine
®
 co-localizes with CD14 at the cell surface and inside cells, but 
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does not co-localizes with TLR4
.
MD-2 complex, suggesting that the mechanism of inhibition 
may result from the uncoupling of CD14 from TLR4
.
MD-2.
21
  
Specific binding of amino glycolipids and aromatic ammonium salts to CD14 (compounds 
IAXO-101, -102, -103, Figure 1), was recently shown by our group.
22, 23
 These compounds are 
active in inhibiting LPS-stimulated TLR4-dependent cytokine production in cells and in 
animals.
24
  
 
Figure 1. Anionic and cationic TLR4 modulators. From the left: lipid A from E. coli, the natural 
TLR4 agonist, synthetic anionic (the antagonist Eritoran
®
) and cationic amphiphiles (diC14-
amidine, IAXO compounds). 
Evaluation of transfer of LOS from the monomeric soluble form of CD14 (sCD14) to His6-
tagged CD14 or MD-2 by co-capture to a metal chelating resin clearly showed that the cationic 
lipids derived from D-glucose or benzylamine inhibit the transfer of LOS from sCD14 to CD14-
His6, but not the transfer of LOS from sCD14 to MD-2.
22
 Finally, saturation transfer difference 
(STD) NMR data demonstrated direct binding of the cationic lipids to CD14, through alkyl 
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chains mainly.
22
 Altogether, these data suggest that the lipid tails of cationic amphiphiles interact 
with the hydrophobic binding site of CD14
25
 and compete with LPS or LOS chains. The 
carbohydrate scaffold in amino glycolipids probably acts by preventing random conformations 
and providing a favorable orientation of the lipid chains that is reminiscent of that found in lipid 
A. Most interestingly, through the interplay of regioselective functionalization methodologies 
and conformational bias, the installation of differentiated cationic and hydrophobic domains in 
carbohydrate platforms can be made compatible with molecular diversity-oriented strategies and 
structure-activity relationship (SAR) studies. As a proof of concept, we have now prepared a 
series of new cationic glycoamphiphiles using the monosaccharide methyl -D-glucopyranoside 
and the disaccharide ,’-trehalose as the sugar cores. Systematic modification of the cationic 
heads and the lipophilic tails and evaluation of their capacity to interfere with TLR4 activation 
and signaling in vitro and in vivo allowed the identification of a drug lead that has been further 
incorporated in gold nanoparticles to test the effect of multivalent presentation on its biological 
activity. 
RESULTS AND DISCUSSION 
Ligand-based rational design. It is known that the self-assembling capabilities and the ability 
of cationic amphiphiles to interact with CD14 as liposomes or micellar aggregates have a strong 
impact on their TLR4 modulatory activity.
17
 Yet, very little is still known on the molecular 
aspects underlying the mechanisms at play, mainly because structural data of cationic 
compounds bound to MD-2 or CD14 receptors are still lacking. Conducting SAR studies on 
series of homologous cationic amphiphiles and relating the biological activity to the aggregation 
properties is expected to provide new insights in this matter. Glucose-derived cationic 
glycolipids are particularly appealing for this purpose. First, the secondary hydroxyls of the 
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glucopyranose ring are well suited anchoring points to link lipophilic chains in a similar 
orientation as the fatty acid acyl chains in lipid A. Second, the incorporation of protonatable 
headgroups at the primary position imparts facial amphiphilicity to the molecule, a biomimetic 
feature that is associated to improved cell-membrane crossing abilities and proneness to form 
supramolecular complexes with complementary biomolecules by either electrostatic or 
hydrophobic interactions.
26
 On these grounds, we have now synthesized amino glycolipids 
derived from methyl -D-glucopyranoside (1-6) and from ,’-trehalose (7-11, Figure 2). The 
latter can be formally considered as dimeric homologues of the glucose amphiphiles. We keep in 
mind that the confluence of two exoanomeric effects at the 1-1 interglycosidic linkage in ,’-
trehalose strongly limits rotation about the glycosidic bonds,
27
 preserving a rigid conformation 
that warrants facial anisotropy after differential functionalization at the primary and secondary 
positions, even in highly constrained constructs.
28
 Both the methyl -D-glucopyranoside and the 
,’-trehalose scaffolds have previously demonstrated their efficiency in the design of TLR4 
modulators with anionic amphiphilic structures.
29,30
 Structural modifications have been projected 
by varying the number, the nature and the length of the lipid chains and the number and 
disposition of amino groups, in order to evaluate how these structural elements influence the 
TLR4 activity.  
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Figure 2. Synthetic monosaccharide and disaccharide protonatable amphiphiles derived, 
respectively, from D -glucose (1-6) and α,α’-trehalose (7-11). 
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Synthesis of glucose-derived cationic glycolipids. The syntheses of the tri-O-alkylated 6-
amino-6-deoxyglucoside derivatives 1 and 2 (Scheme 1) were successfully accomplished by 
reaction of the known methyl 6-azido-6-deoxy--D-glucopyranoside 1231 with hexyl or 
tetradecyl bromide and sodium hydride (13 and 14) followed by reduction of the azido group by 
either catalytic hydrogenation or Staudinger reaction with triphenylphosphine and hydrolysis of 
the corresponding phosphazene intermediate.
32
 The target ether-type amino glycolipids 1 and 2 
were isolated as the corresponding hydrochloride salts.  
Scheme 1. Syntheses of monosaccharides 1-4. 
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Reagents and conditions: a) 1-bromohexane, NaH, DMF, overnight, 48% or 1-
bromotetradecane, NaH, DMF, 55 ºC, 52%; b) H2, Pd/C, MeOH, 2 h, 87%; or PPh3, THF; then, 
NH4OH, 50 ºC, overnight, 82%;c) 1 M LiAlH4 in THF, AlCl3, DCM, Et2O, 83%; d) I2, PPh3, 
imidazole, toluene, 94%; e) HS(CH2)2NHBoc, Cs2CO3, DMF, 60 ºC, 99%; f) 1:1 TFA-DCM, 
80%; g) AlCl3, DCM, Et2O, 87%; h) I2, PPh3, imidazole, toluene, 91%; i) HS(CH2)2NHBoc, 
Cs2CO3, DMF, 60 ºC, 95%; j) 1:1 TFA-CH2Cl2, quant. 
The 2,3-di-O-hexyl and -O-tetradecyl glucose derivatives 3 and 4 were synthesized from the 
corresponding 4,6-O-(p-methoxybenzylidene) protected precursor 15 and 16
33
 respectively, 
which at their turn were obtained by standard alkylation of methyl 4,6-O-(p-
methoxybenzylidene)--D-glucopyranoside.34 The regioselective opening of the acetal ring of 15 
using lithium aluminium hydride (LiAlH4) gave the 4-O-p-methoxybenzyl (PMB) ether 17. 
Compound 16 on his side was completely deprotected on C-4 and C-6 positions using aluminium 
trichloride, affording compound 20. Iodination of the C-6 hydroxyl groups of 17 and 20 using 
Garegg’s conditions35 afforded compounds 18 and 21, which were subjected to cesium 
carbonate-promoted nucleophilic displacement with t-butoxycarbonyl (Boc)-protected 
cysteamine (20 and 22) and final Boc removal in acidic conditions to give compounds 3 and 4. 
The synthetic routes to obtain compounds 5 and 6, having a tertiary and two primary amino 
groups in the cationic head (Scheme 2), are based on the thiourea-forming and the copper(I)-
catalyzed azide-alkyne cycloaddition (CuAAC) reactions, two “click”-type ligation strategies 
already proven very efficient to generate polycationic clusters.
36
 The preparation of 5 started by 
hexanoylation of methyl 6-deoxy-6-iodo--D-glucopyranoside 2335 (24; Scheme 2a) followed by 
nucleophilic displacement of the iodine by Boc-protected cysteamine (25) and carbamate 
hydrolysis, affording the cysteaminyl derivative 26 in 92% overall yield. Condensation of 26 
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with 2-[N,N-bis(2-(N-tert-butoxycarbonylamino)ethylamino]ethyl isothiocyanate
37
 and final 
acid-promoted Boc deprotection provided 5, which was isolated as the dihydrochloride salt. 
Scheme 2. Syntheses of monosaccharides 5 (2a) and 6 (2b). 
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butyl N-(2-mercaptoethyl)carbamate, Cs2CO3, DMF, Ar, overnight, 85%; c) 1:1 TFA-DCM, 
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hexanoic anhydride, DMAP, DMF, Ar, 4 h, 55% b) 3-bis[2-(tert-
butoxycarbonylamino)ethyl]propargylamine, Si-BPA·Cu
+
, 9:1 H2O/
t
BuOH, 85 ºC, 36 h. 78%;  
c) 1:1 TFA/H2O, rt, 1 h, quant; d) 2-(N-tert-butoxyaminocarbonyl)ethyl isothiocyanate, Et3N, 
DCM, overnight, 52%;e) 1:1 TFA/H2O, rt, 1 h, quant. 
The cationic amphiphile 6 was obtained in good yield from azide 12 following a divergent 
synthetic strategy in which the hydrophobic and cationic domains are sequentially installed onto 
the glucopyranoside scaffold. Acylation of 12 with hexanoic anhydride and N,N-
dimethylaminopyridine (DMAP) in DMF afforded triester 28 (Scheme 2b) that was reacted with 
3-bis[2-(tert-butoxycarbonylamino)ethyl]propargylamine
38
 in the presence of silica based 
particles incorporating bis(pyridyl)amine (BPA) Cu(I) chelating agent
39
 to give the triazol adduct 
29 in 78% yield. The use of the solid-supported catalyst has proven advantageous even in multi-
CuAAC ligation strategies, highly simplifying the purification step to a simple filtration 
process.
40
 Acid hydrolysis of the Boc protecting groups in 29 provided the corresponding 
triamine 30, which was next reacted with 2-(N-tert-butoxycarbonylamino)ethyl isothiocyanate
41
 
to give bis(thiourea) 31. Final hydrolysis of the Boc protecting groups, led to the target 
compound 6. 
Syntheses of trehalose-derived cationic glycolipids. The strategies implemented for the 
preparation of the ,’-trehalose amino glycolipids 7-11 parallel those above commented for the 
corresponding ether- (1-4) or ester-type (5-7) methyl -D-glucopranoside counterparts. Thus, 
compounds 7 and 8 were obtained in good overall yield in an efficient five-step synthesis starting 
from 6,6’-di-O-trityl-’-trehalose 3242 after alkylation of the six secondary hydroxyl groups 
(33 and 34), trityl cleavage with p-toluenesulfonic acid in DCM-MeOH (35 and 36), Garegg’s 
iodination of the primary hydroxyls (37 and 38), nucleophilic displacement of the iodines with 
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Boc-protected cysteamine (39 and 40) and hydrolysis of the carbamate groups (Scheme 3). The 
hexanoylated analogue 9 was similarly obtained from 6,6’-dideoxy-6,6’-diiodo-,’-trehalose 
41
43
 by esterification of the secondary hydroxyls (42), incorporation of the Boc-protected 
cysteamine substituents at the primary positions (43) and final deprotection (Scheme 4). 
Scheme 3. Syntheses of trehalose derivatives 7 and 8. 
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38; d) HS(CH2)2NHBoc, Cs2CO3, DMF, 60 ºC, overnight, 85% for 39 and 99% for 40; e) 1:1 
TFA/DCM, rt, 15 min, quant. for 7, 98% for 8. 
Scheme 4. Synthesis of trehalose derivative 9. 
 
Reagents and conditions. a) HS(CH2)2NHBoc, Cs2CO3, DMF, 60 ºC, 24 h, 58%; b) 1:1 
TFA/DCM, rt, 15 min, quant. 
The cationic trehalose amphiphiles 10 and 11 were prepared starting from the common diazide 
precursor 44, readily accessed by nucleophilic displacement of the iodine in 42 with sodium 
azide, by CuAAC ligation using the silica-supported Si-BPA-Cu
+ 
catalyst. Thus, sequential 
reaction of 44 with N-Boc-propargylamine (45), carbamate hydrolysis (46), thiourea-coupling 
with Boc-protected 2-aminoethyl isothiocyanate (47) and final Boc removal yielded the 
diaminoethylthioureido adduct 10. Alternatively, the CuAAC coupling of 44 with 3-bis[2-(tert-
butoxycarbonylamino)ethyl]propargylamine (48) followed by carbamate hydrolysis afforded 
compound 11 (Scheme 5).  
Scheme 5. Syntheses of trehalose derivatives 10 and 11. 
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Reagents and conditions. a) N-tert-butoxycarbonylpropargylamine, Si-BPA·Cu
+
, 9:1 
H2O/
t
BuOH, 24 ºC, 36 h, quant; b) 1:1 TFA/H2O, rt, 1 h, 97%; c) tert-butyl-N-(2-
isothiocyanoethyl)carbamate, Et3N, DCM, overnight, 67%; d) 1:1 TFA/H2O, rt, 1 h, quant; e) 3-
bis[2-(tert-butoxycarbonylamino)ethyl]propargylamine, Si-BPA·Cu
+
, 9:1 H2O/
t
BuOH, reflux, 36 
h, 91%; f) 1:1 TFA/H2O, rt, 1 h, quant. 
TLR4 modulation in HEK-Blue
TM
 cells. 
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Cationic amphiphiles 1-11 were first screened for their capacity to interfere with TLR4 
activation and signaling on HEK-Blue
TM
 cells. HEK-Blue
TM
 cells are stably transfected with 
TLR4, MD-2, and CD14 genes. In addition, these cells stably express an optimized alkaline 
phosphatase gene engineered to be secreted (sAP), placed under the control of a promoter 
inducible by several transcription factors such as NF-B and AP-1.29 This reporter gene allows 
monitoring the activation of TLR4 signal pathway by endotoxin. Compounds 5, 9-11 were 
inactive in stimulating TLR4 signal when provided alone while inhibited in a dose-dependent 
way the LPS-stimulated TLR4 signal (Table 1). Compounds 1-4 and 6-8 resulted inactive or with 
very low activity both as agonists and antagonists. 
Table 1. TLR4 antagonist activity of cationic glycolipids 5, 9-11 on HEK-Blue
TM
 cells, HEK293 
hMD-2/hTLR4 and HEK293 mMD-2/mTLR4 stimulated with E. coli O55:B5 LPS (10 nM). 
 IC50(µM) 
Compound HEK-BlueTM HEK293 
hMD-2·hTLR4 
HEK293 
mMD-2·mTLR4 
5 3.7±0.4 3.9±1.5 3.3±1.2 
9 1.3±0.1 1.4±0.3 0.8±0.2 
10 5.0±1.0 0.6±0.02 0.6±0.03 
11 0.6±0.05 0.2±0.02 0.2±0.03 
 
The lack of significant activity of all compounds bearing C6 or C14 ether-linked lipophilic chains, 
namely compounds 1-4 and 7-8, strongly suggests that the presence of ester-type linkages at the 
hydrophobic domain is a primary structural requirement to elicit LPS-antagonist behavior in 
cationic glycolipids. From the acylated sub-library all compounds are active with the exception 
of compound 6, meaning that the cationic head also has an impact on the TLR4 antagonist 
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activity Among these, the trehalose-based disaccharides 9-11, bearing more compact cationic 
headgroups, showed higher potency as TLR4 antagonists than monosaccharide 5. The observed 
trend points to a positive relationship between well-ordered facial amphiphilicity and TLR4 
antagonist activity of cationic glycolipids. In agreement with this, disaccharide 11 with six 
hexanoyl chains and six protonable amino groups oriented towards opposite faces in a rather 
compact arrangement (Figure 3) proved to be the most active TLR4 antagonist. Compounds 5, 9, 
10, 11 were further tested for their toxicity by a standard MTT viability test and all resulted non 
toxic or with very low toxicity in the concentration range used to test their activity (Supp. Info.). 
 
Figure 3. 3D molecular model of compound 11 (cationic headgroups in red, triazol linkers in 
blue, ,’-trehalose scaffold in orange, hexanoyl chains in green) evidencing its compact facial 
amphiphilic character. Hydrogens have been omitted for the sake of clarity. 
Activity on HEK293 cells transfected with human and murine MD-2
.
TLR4.  
Biologically active cationic glycolipids 5, 9, 10 and 11 were further examined for their capacity 
to stimulate or to inhibit LPS-induced TLR4 activation and signaling in HEK293 cells 
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transfected with human or murine TLR4
 
and MD-2 and a dual luciferase reporter gene (Figure 
4).  
 
Figure 4. Dose-dependent inhibition of LPS-stimulated TLR4 activation by synthetic 
glycolipids. HEK293 cells transfected with human MD-2·TLR4 (red line) or murine MD-
2/TLR4 (blue line), were treated with increasing concentrations of compounds and stimulated 
with LPS (5 nM). Normalized data are representative of three independent experiments. 
In the absence of LPS, none of the cationic glycolipids stimulate TLR4 signaling (no agonist 
activity) in cells transfected with hMD-2
.
hTLR4 or mMD-2
.
mTLR4. Conversely, in the presence 
of LPS all compounds were able to inhibit human and murine MD-2·TLR4 activation in a 
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concentration-dependent manner. The antagonist potency (IC50 values, Table 1) of 5, 9, 10 and 
11 was similar in cells transfected with human and mouse receptors and also very similar to the 
activity found in HEK-Blue
TM
 cells (Table 1). In cells transfected with hMD-2
.
hTLR4 or mMD-
2
.
mTLR4, triacylated monosaccharide 5 and hexacylated disaccharide 9 were less active (IC50 = 
3.3-3.9 M and 0.8-1.4 M, respectively) than disaccharides 10 and 11 (IC50 = 0.6  M and 0.2 
M, respectively). The high potency of trehalose-derived glycolipids 9 and 11 in inhibiting both 
mouse and human MD-2
.
TLR4 signals is reminiscent of the activity of synthetic Eritoran
®
 that 
has potent TLR4 antagonist activity in all species.
16, 44
 In contrast, natural lipid IVa is agonist on 
murine and antagonist on human TLR4.
45
  
Experiments on murine macrophages. 
The activity of compounds 5, 9 and 11 on LPS-induced TLR4 signaling in bone marrow-derived 
murine macrophages (BMDM) was subsequently tested. Compounds 5 and 9 showed very 
low/no activity in activating TLR4 or in inhibiting LPS-stimulated TLR4 signal (Supp. Info.), 
while compound 11 (Figure 5) gave a concentration-dependent inhibition of IL-6 and TNF-α 
production at concentrations of 1 and 2 M (Figure 5), while at 0.1 and 0.5 M concentrations 
had no effect or a slightly potentiating effect. 
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Figure 5. BMDM were treated with increasing concentrations (0-2 μM) of compound 11 in 
RPMI+FBS 10% in the presence of LPS, administered 1 hour after the treatment with synthetic 
compound. The ELISA assay, performed after overnight incubation, revealed a dose dependent 
decrease of LPS-induced IL-6 and TNF-α production. Cytokines productions in cells not treated 
with LPS are reported as negative controls.   
Aggregation properties of cationic glycolipids 
Cationic lipids can spontaneously assembly into liposomal structures. Some cationic liposomes 
induce the expression of pro-apoptotic and pro-inflammatory mediators through the activation of 
cellular pathways.
17
 However, it is still controversial if the initiation of inflammatory and 
apoptotic response is due to specific interaction with receptors at the cell surface or to the 
internalization of liposomes into cells through endocytosis and endocytosis-like mechanisms 
followed by interaction of charged compounds with downstream effectors. In the particular case 
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of cationic lipids modulating TLR4 activity, there is no information available on whether 
aggregated species or single molecules are the active species. To have an insight in this question, 
we have determined the critical micelle concentrations (CMC) of cationic glycolipids 5, 9, 10 
and 11 using an established technique based on the polarity-induced change in the fluorescence 
spectra of pyrene when incorporated in micelle formed by synthetic compounds (Table 2).
46
 In 
all cases the CMC values of active compounds are higher than the corresponding IC50 values as 
TLR4 antagonists, suggesting that the biologically active species are prevalently single 
molecules in solution. 
Table 2. Critical micelle concentrations (CMC) in aqueous environment of TLR4 antagonists. 
Compound CMC (M)  
5 59.7 ± 7.4  
9 97.7 ± 10.0  
10 10.9 ± 2.1 
11 350.5 ± 70.5 
 
Synthesis and biological activity of gold nanoparticles coated with glycolipid 11 
LPS is an amphiphilic molecule and it is mainly present in the form of micellar aggregates in a 
concentration range that is relevant for its biological activity. It has been recently proposed that 
the multiple presentation of LPS or other TLR4 ligands on nanoparticles could be a way to 
potentiate the agonist or antagonist action of chemicals by mimicking the 3D-structure of LPS 
aggregates.
47, 48
 Moreover, the possibility of in vitro and/or in vivo delivery based on NP is 
considered advantageous for clinical development, as it can maximize the effectiveness of drugs, 
minimize the invasiveness and toxic side effects and speed up the clinical development program. 
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To test the suitability of this approach in the case of cationic glycolipids, the preparation and 
biological evaluation of gold nanoparticles coated with the most active compound 11 has been 
undertaken. Colloidal gold nanoparticles were synthesized by a variation of the Brust-Schiffrin 
method
49
 and coated by surface adsorption with the ,’-trehalose derivative 11. The resulting 
cationic glycolipid-modified nanoparticles (11-NP) kept a small size with low-polydispersity. 
Most interestingly, they retained the biological activity without apparent increase in cytotoxicity. 
These results represent a proof of concept of the possibility of developing nanoparticulate 
systems based on cationic glycolipids as modulators of TLR4 signaling pathway, an approach 
previously demonstrated only for LPS itself.
47
 Based on these data, the prepared 11-NP 
nanoparticles were engaged in an in vivo assay. The inhibitory activity of the nanoparticles 
coated with glycolipid 11 was tested on HEK293 cells. They exhibited strong LPS-inhibitory 
activity already at very low concentrations (Figure 6 A, B) on human as well as murine MD-
2·TLR4 receptor complex.  
 
Figure 6. Dose-dependent TLR4 antagonism in HEK293 cells treated with  DTT-Au-NP-11. 
HEK293 cells were transfected with NF-B-dependent luciferase and constitutive Renilla 
luciferase reporter plasmids as well as with (A) human or (B) murine MD-2 and TLR4 plasmids. 
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The indicated amount of the DTT-Au-NP-11 was added to the cells, followed one hour later by 
stimulation with LPS. Luciferase activity was measured 16 hours later.  
In vivo activity 
Since the synthetized compounds exhibited strong inhibition of the LPS-induced MD-2·TLR4 
activation in vitro, we next wished to determine their inhibitory potential in vivo. All four 
selected candidates (5, 9, 10 and 11) potently inhibited the LPS-induced immune activation in 
C57/Bl6 mice (Figure 7). The strongest inhibition was exhibited by compound 11, which totally 
abolished LPS-induced immune activation. Results in Figure 8 show that compounds 5, 9, 10 
and 11 are strong MD-2·TLR4 inhibitors not only in vitro but also in vivo.  
 
 
Figure 7. in vivo activity of cationic amphiphiles. C57/Bl6 mice were injected i.p. with the 
indicated compounds (2·10
-7
 mol/mouse), followed 1 hour later by i.p. injection of LPS (1·10
-9
 
mol/mouse). Three hours later sera were collected and TNF-α concentration was determined by 
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ELISA. (data shown with mean and standard error, N=5-6) two-tailed t-test (* p<0,1; ** p<0,01 
– compared to »LPS«) (# not significant – compared to »none«) 
Conclusions and perspectives 
New cationic amphiphiles 1-11 based on monosaccharide and disaccharide glycolipid scaffolds 
have been designed, synthesized and their capacity to modulate TLR4 activation and signaling 
evaluated. Glucose-based compound 5 and trehalose-based compounds 9-11 were active in 
inhibiting the LPS-triggered TLR4 activation and signaling in HEK cells with IC50 values 
ranging from about 5 to 0.2 M. The cell toxicity of these molecules is low, and the potency of 
TLR4 antagonism is in the same order of magnitude of the best synthetic TLR4 antagonists so 
far tested by us
29
 and other groups.
30
 The active molecules inhibited the TLR4 signal in HEK 
cells transfected with human and murine MD-2
.
TLR4 complexes with very similar potency, 
similarly to the very efficient TLR4 antagonist Eritoran
®
 and differently from the natural TLR4 
antagonist lipid IVa that has species-specific activity (antagonist on human and agonist on mice 
MD-2
.
TLR4). Compounds 5, 9, 10 and 11 significantly inhibited LPS-triggered IL-6 production 
in mice, with compound 11 showing the most evident effect. Since these compounds are active 
in vitro and in vivo, and show low toxicity, they represent good leads for the development of 
drugs targeting TLR4 signaling.  
The biological evaluation of active compounds compared to inactive, structurally related 
monosaccharides (compounds 1-4, 6) and disaccharides (compounds 7 and 8), suggests some 
general structure-activity relationships in this type of compounds: i) the presence of acyl 
lipophilic chains at the hydrophobic domain seems to be a primary requisite since all compounds 
with ether bonds are inactive, ii) the higher in vitro and in vivo activity of compound 11 suggests 
that the trehalose scaffold favors the biological activity, probably by providing a well-ordered 
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facial amphiphilic character. Compound 11 adsorbed on gold nanoparticles (11-NP) is still active 
as TLR4 antagonist in cells, but the high toxicity of these functionalized nanoparticles could 
prevent their use in vivo as carriers for TLR4 antagonists. 
Finally, the experimentally determined CMC values for cationic glycolipids 5, 9-11 are one order 
of magnitude higher than the corresponding IC50 as TLR4 antagonists, suggesting that they are 
active as single monomers in solution. This very likely means that specific molecular interaction 
with CD14 and MD-2 receptors regulate the TLR4 activity of these compounds. It will be 
important in the future to define more precisely the molecular determinants of the interaction 
with CD14 and MD-2 receptors to allow a structure-based rational design of cationic TLR4 
modulators. 
EXPERIMENTAL SECTION 
General Synthetic Methods. Optical rotations were measured at 20 ± 2 °C in 1-dm tubes on a 
Jasco P-2000 polarimeter. Ultraviolet-visible (UV) spectra were recorded in 1-cm tubes on a 
Jasco V-630 spectrophotometer. Infrared (IR) spectra were recorded on a Jasco ATR MIRacle
TM
 
spectrophotometer. 
1
H (and 
13
C NMR) spectra were recorded at 300 (75.5), 500 (125.7) MHz 
with Bruker 300 AMX, 500 AMX and 500 DRX. 1D TOCSY, 2D COSY, HMQC and HSQC 
experiments were used to assist on NMR assignments. Thin-layer chromatography (TLC) was 
carried out on aluminium sheets coated with Sílica Gel 60 F254 Merck with visualization by UV 
light and by charring with 10% H2SO4. With preparative purposes, column chromatography was 
carried out on Silica Gel 60 F254 Merck. ESI mass spectra were recorded in the positive mode on 
Bruker Daltonics esquire6000™ ion-trap mass spectrometer. Typically, samples were dissolved 
in appropriate volumes of deionised water to give samples concentration of 50 mg/L. Aliquots 
were mixed with 25:25:1 deionised water-methanol-trifluoroacetic acid, generally in a ratio of 
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1:10, to give a total volume of 200 L. Samples were introduced by direct infusion, using a 
Cole-Parmer syringe at a flow rate of 2 L/min. Ions were scanned between 300 and 3000 Da 
with a scan speed of 13000 Da/s at unit resolution using resonance ejection at the multipole 
resonance of one-third of the radio frequency ( = 781.25 kHz). Calibration of the mass 
spectrometer was performed using ES tuning mix (Hewlett Packard). Recorded data were 
processed using Bruker Daltonics Esquire 5.0 software (Bruker). Elemental analyses were 
carried out at the Instituto de Investigaciones Químicas (Sevilla, Spain) using an elemental 
analyser Leco CHNS-932 or Leco TruSpec CHN.  
Methyl 6-azido-6-deoxy--D-glucopyranoside,28 methyl 4,6-O-(4-methoxybenzylidene)--D-
glucopyranoside,
34
 methyl 6-deoxy-6-iodo--D-glucopyranoside,35 2-[N,N-bis(2-(N-tert-
butoxyaminocarbonyl)ethylamino]ethyl isothiocyanate,
37
 6,6'-dideoxy-6,6'-diiodo-,'-trehalose 
41,
43
  6,6’-di-O-trityl-’-trehalose 32,42 N-(2-isothiocyanoethyl) tert-butylcarbamate,41 and 3-
bis[2-tert-butoxycarbonylamino)ethyl]propargylamine
38
 were obtained according to described 
procedures. Purity of all final compounds was confirmed to be ≥95% by 1H NMR and 
combustion microanalysis. 
Methyl 6-Azido-6-deoxy-2,3,4-tri-O-hexyl--D-glucopyranoside (13). To a solution of methyl 
6-azido-6-deoxy--D-glucopyranoside (0.40 m, 1.82 mmol) in dry DMF (9 mL), NaH (0.65 g, 
16.42 mmol) was added, under Ar atmosphere, at 0 ºC. Then 1-bromohexane (2.3 mL, 16.42 
mmol) was added dropwise and the reaction mixture was stirred overnight at rt. The solvent was 
evaporated and the residue diluted in DCM (10 mL) and washed with H2O (2 x 10 mL). The 
organic layer was dried (MgSO4), concentrated and purified by column chromatography (1:30 
EtOAc-cyclohexane). Yield 48% (0.50 m, 1.06 mmol ). Rf = 0.34 (1:18 EtOAc-cyclohexane); 
[]D = +90.0 (c 1.0, DCM); IR: max = 2099, 1094 cm
-1 
; 
1
H NMR (300 MHz, CDCl3): δ = 4.74 
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(d, 1 H, J1,2 = 3.5 Hz, H-1), 3.79, 3.64, 3.58 (m, 6 H, OCH2), 3.67 (m, 1 H, H-5), 3.64-3.24 (m, 2 
H, H-3, H-6a), 3.39 (s, 3 H, OCH3), 3.35 (m, 1 H, H-6b), 3.23 (dd, 1 H, J2,3 = 9.6 Hz, H-2), 3.12 
(t, 1 H, J3,4 = J4,5 = 9.3 Hz, H-4), 1.55 (m, 6 H, CH2), 1.27 (m, 18 H, CH2), 0.86 (m, 9 H, CH3); 
13
C NMR (75.5 MHz, CDCl3): δ = 98.0 (C-1), 81.3 (C-3), 80.7 (C-2), 78.8 (C-4), 73.7, 73.6, 71.8 
(OCH2), 70.2 (C-5), 55.2 (OCH3), 51.5 (C-6), 31.7-22.6 (CH2), 14.3 (CH3); ESI MS: m/z = 965.8 
[2M + Na]
+
, 494.6 [M + Na]
+
. Anal. Calcd for C25H49N3O5: C, 63.66; H, 10.47; N, 8.91. Found: 
C, 63.72; H, 10.97; N, 8.33. 
Methyl 6-Amino-6-deoxy-2,3,4-tri-O-hexyl--D-glucopyranoside Hydrochloride (1). To a 
solution of 13 (0.15 g, 0.32 mmol) in degassed MeOH (12 mL), Pd/C (10%, 0.06 g) was added 
and the mixture was stirred under H2 atmosphere (1 bar) at rt until complete consumption of the 
starting compound. The catalyst was filtered off, the solution concentrated, and the resulting 
residue purified by column chromatography (1:9 EtOAc-cyclohexane → 45:5:3 EtOAc-EtOH-
H2O) and freeze-dried from 0.1 N HCl solution. Yield 87% (0.12 g, 0.26 mmol) ; []D = +83.0 (c 
1.0, DCM); 
1
H NMR (300 MHz, CD3OD): δ = 4.82 (d, 1 H, J1,2 = 3.4 Hz, H-1), 3.81, 3.64, 3.56 
(m, 6 H, OCH2), 3.65 (m, 1 H, H-5), 3.53 (t, 1 H, J2,3 = J3,4 = 9.3 Hz, H-3), 3.41 (s, 3 H, OCH3), 
3.25 (dd, 1 H, H-2), 3.11 (dd, 1 H, J6a,6b = 13.1 Hz, J5,6a = 2.7 Hz, H-6a), 3.01 (t, 1 H, J4,5 = 9.3 
Hz, H-4), 2.84 (dd, 1 H, J5,6b = 8.5 Hz, H-6b), 1.56 (m, 6 H, CH2), 1.33 (m, 18 H, CH2), 0.91 (m, 
9 H, CH3); 
13
C NMR (75.5 MHz, CD3OD): δ = 99.1 (C-1), 82.6 (C-3), 81.8 (C-2), 81.1 (C-4), 
74.5, 74.3, 72.2 (OCH2), 70.7 (C-5), 55.8 (OCH3), 42.9 (C-6), 33.0-24.2 (CH2), 14.4 (CH3); 
ESIMS: m/z = 891.7 [2 M + H]
+
, 446.5 [M + H]
+
. Anal. Calcd for C25H51NO5·HCl: calcd. C, 
62.28; H, 10.87; N, 2.91. found: C, 62.33; H, 10.69; N, 2.70.  
Methyl 6-Azido-6-deoxy-2,3,4-tri-O-tetradecyl--D-glucopyranoside (14). To a solution of 
methyl 6-azido-6-deoxy--D-glucopyranoside (0.28 g, 1.30 mmol) in dry DMF (4 mL), NaH  
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(0.55 mg, 13.60 mmol) was added, under Ar atmosphere, at 0 ºC. Then 1-bromotetradecane (4.1 
mL, 13.60 mmol) was added dropwise, and the reaction mixture was stirred overnight at 55 ºC. 
The solvent was evaporated and the residue diluted in DCM (10 mL) and washed with H2O (2 x 
10 mL). The organic layer was dried (MgSO4), concentrated and purified by column 
chromatography (cyclohexane → 1:40 EtOAc-cyclohexane). Yield 42%  (0.45 g, 0.26 mmol) . 
Rf = 0.25 (1:15 EtOAc-cyclohexane); []D = +52.1 (c 1.0, DCM); IR: max = 2100, 1096 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3): δ = 4.76 (d, 1 H, J1,2 = 3.4 Hz, H-1), 3.79, 3.64, 3,58 (m, 6 H, OCH2), 
3.69 (m, 1 H, H-5), 3.66-3.44 (m, 2 H, H-3, H-6a), 3.39 (s, 3 H, OCH3), 3.37 (dd, 1 H, J6a,6b = 
13.3 Hz, J5,6b = 5.5 Hz, H-6b), 3.25 (dd, 1 H, J2,3 = 9.4 Hz, H-2), 3.13 (t, 1 H, J3,4 = J4,5 = 9.4 Hz, 
H-4), 1.57 (m, 6 H, CH2), 1.27 (m, 66 H, CH2), 0.86 (m, 9 H, CH3); 
13
C NMR (75.5 MHz, 
CDCl3): δ = 98.0 (C-1), 81.3 (C-3), 80.7 (C-2), 78.8 (C-4), 73.7, 73.6, 71.8 (OCH2), 70.2 (C-5), 
55.2 (OCH3), 51.5 (C-6), 31.9-22.7 (CH2), 14.1 (CH3); ESI MS: m/z = 830.8 [M + Na]
+
. Anal. 
Calcd for C49H97N3O5: C, 72.81; H, 12.10; N, 5.20. Found: C, 72.89; H, 11.87; N, 4.88. 
Methyl 6-Amino-6-deoxy-2,3,4-tri-O-tetradecyl--D-glucopyranoside Hydrochloride (2). To 
a solution of 14 (0.15 g, 0.19 mmol) in THF (16.4 mL), TPP (0.10 g, 0.39 mmol) was added and 
the mixture was stirred at rt for 15 min. Then NH4OH (1.6 mL) was added, the solution was 
stirred overnight at 50 ºC and then concentrated. The resulting residue was purified by column 
chromatography (EtOAc→9:1 DCM-MeOH) and freeze-dried from 10:1 H2O-HCl 0.1 N 
solution. Yield 82% (0.13 mg, 0.16 mmol); []D = +43.2 (c 1.0, DCM); IR: max = 1092 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3): δ = 4.79 (d, 1 H, J1,2 = 3.4 Hz, H-1), 3.78, 3.60, 3.55 (m, 7 H, OCH2, 
H-3), 3.73 (m, 1 H, H-5), 3.46 (s, 3 H, OCH3), 3.27 (m, 1 H, H-6ª), 3.22 (dd, 1 H, J1,2 = 9.5 Hz, 
H-2), 2.95 (m, 2 H, H-4, H-6b), 1.55 (m, 6 H, CH2), 1.25 (m, 66 H, CH2), 0.87 (t, 9 H, 
3
JH,H = 6.6 
Hz, CH3); 
13
C NMR (75.5 MHz, CD3OD): δ =98.0 (C-1), 81.0 (C-3), 80.4 (C-2), 79.9 (C-4), 77.2 
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(C-5), 73.7, 73.5, 71.8 (OCH2), 67.1 (C-6), 55.9 (OCH3), 31.9-22.7 (CH2), 14.0 (CH3); ESI MS: 
m/z = 783.0 [M + H]
+
. Anal. Calcd for C49H99NO5·HCl: calcd. C, 71.88; H, 12.31; N, 1.71; 
found: C, 71.64; H, 12.26; N, 1.49. 
Methyl 4,6-O-(4-Methoxybenzylidene)-2,3-di-O-hexyl--D-glucopyranoside (15). To a 
solution of methyl 4,6-O-(4-methoxybenzylidene)--D-glucopyranoside (0.80 g, 2.57 mmol) in 
DMF (8 mL), NaH (0.62 g, 15.42 mmol) was added. Then, 1-bromohexane (1.8 mL, 12.85 
mmol) was added dropwise and the resulting mixture was stirred at 60 ºC overnight. After 
cooling to rt, the reaction was quenched with MeOH (2 mL) and the solution was stirred for 20 
min. Solvents were then evaporated and the residue was diluted with EtOAc (50 mL) and citric 
acid (satd aq soln, 40 mL). The layers were separated and the organic phase was washed with 
H2O (3 x 40 mL), dried (MgSO4), evaporated, and purified by column chromatography (1:9 
EtOAc-cyclohexane). Yield 57% (0.71 g, 0.15 mmol); Rf = 0.44 (1:9 EtOAc-cyclohexane); []D 
= +37.2 (c 1.0, DCM); 
1
H NMR (300 MHz, CDCl3):  = 7.39, 6.87 (2 d, 4 H, A2X2, aromatics), 
5.49 (s, 1 H, PhCH), 4.78 (d, 1 H, J1,2 = 3.8 Hz, H-1), 4.25 (dd, 1 H, J6a,6b = 9.6 Hz, J5,6a = 4.5 
Hz, H-6a), 3.80 (s, 3 H, PhOCH3), 3.76 (m, 1 H, H-5), 3.72 (t, 1 H, J2,3 = J3,4 = 9.2 Hz, H-3) 
3.72-3.57 (m, 5 H, H-6b, OCH2), 3.47 (t, 1 H, J4,5 = 9.2 Hz, H-4), 3.42 (s, 3 H, OCH3), 3.34 (dd, 
1 H, H-2), 1.66-1.49 (m, 4 H, CH2), 1.41-1.18 (m, 12 H, CH2), 0.88, 0.84 (2 t, 6 H, 
3
JH,H = 6.5 
Hz, CH3);
13
C NMR (75.5 MHz, CDCl3):  = 159.9-113.5 (Ph), 101.2 (PhCH), 99.1 (C-1), 81.9 
(C-4), 80.4 (C-2), 78.2 (C-3), 73.4, 72.2 (OCH2), 69.0 (C-6), 62.4 (C-5), 55.6 (OCH3), 31.7-22.6 
(CH2), 14.0 (CH3); ESI MS: m/z: 519.5 [M + K]
+
, 503.6 [M + Na]
+
. Anal. Calcd for C27H44O7: C, 
67.47; H, 9.23. Found: C, 67.54; H, 9.30. 
Methyl 4,6-O-(4-Methoxybenzylidene)-2,3-di-O-tetradecyl--D-glucopyranoside (16).31 To a 
solution of methyl 4,6-O-(4-methoxybenzylidene)--D-glucopyranoside (0.80 g, 2.57 mmol) in 
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DMF (8 mL), NaH (60% suspension in mineral oil, 0.62 g, 15.42 mmol) was carefully added in 
small portions. Tetradecylbromide (3.8 mL, 12.85 mmol) was added dropwise and the resulting 
mixture was stirred at 60 ºC overnight. After cooling to rt, the mixture was quenched with 
methanol (2 mL) then the solution was stirred for 20 min. Solvents were then evaporated and the 
residue was diluted with EtOAc (50 mL). Citric acid (satd aq soln, 40 mL) was added, the layers 
were separated, the organic layer was washed with water (3 x 40 mL), dried (Na2SO4) and 
evaporated. Flash column chromatography on silica gel of the residue (1:9 EtOAc-cyclohexane) 
afforded 16. Yeld 74% (1.33 g, 1.89 mmol). Rf = 0.65 (1:9 EtOAc-cyclohexane); []D = +23.3 (c 
1.0 in CHCl3); 
1
H NMR (300 MHz, CDCl3):  = 7.40, 6.87 (2 d, 4 H, A2X2, aromatics), 5.49 (s, 1 
H, PhCH), 4.78 (d, 1 H, J1,2 = 3.8 Hz, H-1), 4.25 (dd, 1 H, J6a,6b = 9.6, J5,6a = 4.6 Hz, H-6a), 3.80 
(s, 3 H, OCH3), 3.76 (m, 1 H, H-5), 3.75-3.59 (m, 6 H, H-3, H6b, OCH2), 3.47 (t, 1 H, J3,4 = J4,5 
= 9.3 Hz, H-4), 3.42 (s, 3 H, OCH3), 3.34 (dd, 1 H, J2,3 = 9.3, H-2), 1.70-1.49 (m, 4 H, CH2), 
1.22 (bs, 44 H, CH2), 0.87 (t, 6 H, 
3
JH,H = 5.8 Hz, CH3). 
13
C NMR (75.5 MHz, CDCl3):  = 
159.1, 130.0, 127.3, 113.5 (Ph), 101.2 (PhCH), 99.1 (C-1), 81.9 (C-4), 80.4 (C-2), 78.2 (C-3), 
73.4, 72.3 (OCH2), 69.0 (C-6), 62.4 (C-5), 55.2 (OCH3), 31.9-22.7 (CH2), 14.1 (CH3). ESI MS: 
m/z: 503.6 [M + Na]
+
, 519.5 [M + K]
+
. 
Methyl 2,3-Di-O-hexyl-4-O-(p-methoxybenzyl)--D-glucopyranoside (17). To a solution of 15 
(0.71 g, 1.48 mmol) in a mixture of Et2O-DCM (2:1, 75 mL), under Ar atmosphere, 1 M LiAlH4 
in THF (7.4 mL, 7.40 mmol) and AlCl3 (0.81 g, 6.06 mmol) in Et2O (25 mL) were added 
dropwise, and the resulting mixture was refluxed for 4 h. After cooling to rt, EtOAc (250 mL) 
and H2O (250 mL) were added. The organic layer was washed with brine (2 x 200 mL), dried 
(MgSO4), evaporated and purified by column chromatography (1:2 EtOAc-cyclohexane). Yield 
83% (0.60 g, 1.22 mmol); Rf = 0.26 (1:2 EtOAc-cyclohexane); []D = +76.2 (c 1.0, DCM); IR: 
 31 
max= 1076, 1035cm
-1
; 
1
H NMR (300 MHz, CDCl3):  =7.26, 6.87 (A2X2 system, 4 H, 
aromatics), 4.81 (d, 1 H, 
2
JHa,Hb = 10.8 Hz, PhCHa), 4.75 (d, 1 H, J1,2 = 3.5 Hz, H-1), 4.57 (d, 1 
H, PhCHb), 3.86 (m, 1 H, OCH2), 3.79 (s, 3 H, PhOCH3), 3.77-3.64 (m, 3 H, H-6a, H-6b, 
OCH2), 3.68 (m, 1 H, H-3), 3.67-3.53 (m, 3 H, OCH2, H-5), 3.42 (t, 1 H, J3,4 = J4,5 = 9.5 Hz, H-
4), 3.37 (s, 3 H, OCH3), 3.26 (dd, 1 H, J2,3 = 9.5 Hz, H-2), 1.75 (bs, 1 H, OH), 1.64-1.57 (m, 4 H, 
CH2), 1.37-1.28 (m, 12 H, CH2), 0.88 (t, 6 H, 
3
JH,H = 7.0 Hz, CH3), 0.87 (t, 6 H, 
3
JH,H = 6.8 Hz, 
CH3); 
13
C NMR (75.5 MHz, CDCl3):  =159.3-113.8 (Ph), 98.0 (C-1), 81.6 (C-3), 80.8 (C-2), 
77.1 (C-4), 74.5 (PhCH2), 73.7, 71.7 (OCH2), 70.6 (C-5), 62.0 (C-6), 55.2, 55.0 (OCH3), 31.8-
22.6 (CH2), 14.0 (CH3); ESI MS: m/z: 505.6 [M + Na]
+
, 521.5 [M + K]
+
. Anal. Calcd for 
C27H46O7: C, 67.19; H, 9.61; found: C, 66.92; H, 9.67. 
Methyl 6-Deoxy-2,3-di-O-hexyl-6-iodo-4-O-(p-methoxybenzyl)--D-glucopyranoside (19). 
To a solution of 17 (0.60 g, 1.23 mmol) in toluene (25 mL) TPP (0.49 g, 1.85 mmol) and 
imidazole (0.25 g, 3.70 mmol) were added. Iodine (0.49 g, 1.73 mmol) was added in portions 
and the resulting solution was stirred at 70 ºC for 5 h. After cooling at rt, NaHCO3 sat. (25 mL) 
was added and the mixture was stirred for 5 min. Additional iodine was added and the mixture 
was stirred for 10 min. Then Na2S2O3 aq. 10% was added to remove the iodine excess. The 
organic layer was separated, washed with H2O (3 x 25 mL), dried (MgSO4), filtered, 
concentrated and purified by column chromatography (1:4 EtOAc-cyclohexane). Yield 94% 
(0.69 g, 1.16 mmol) . Rf = 0.52 (1:4 EtOAc-cyclohexane); []D = +84.3 (c 1.0, DCM); 
1
H NMR 
(300 MHz, CDCl3):   = 7.26, 6.88 (A2X2 system, 4 H, , aromatics), 4.87 (d, 1 H, 
2
JHa,Hb = 10.6 
Hz, PhCHa), 4.77 (d, 1 H, J1,2 = 3.4 Hz, H-1), 4.62 (d, 1 H, PhCHb),  3.87 (m, 1 H, CH2), 3.80 
(s, 3 H, PhOCH3), 3.75-3.64 (m, 2 H, H-3, OCH2), 3.63-3.50 (m, 2 H, OCH2), 3.46 (dd, 1 H, 
J6a,6b = 10.4 Hz, J5,6a = 2.4 Hz,  H-6a), 3.42 (s, 3 H, OCH3), 3.37 (m, 1 H, H-5), 3.35-3.26 (m, 2 
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H, H-2, H-6b), 3.24 (t, 1 H, J3,4 = J4,5 = 9.0 Hz, H-4), 1.66-1.55 (m, 4 H, CH2), 1.39-1.25 (m, 12 
H, CH2), 0.88 (t, 6 H, 
3
JH,H = 6.5 Hz, CH3), 0.87 (t, 6 H, 
3
JH,H = 6.8 Hz, CH3); 
13
C NMR (75.5 
MHz, CDCl3):  =159.4-113.9 (Ph), 98.0 (C-1), 81.2 (C-3), 81.1 (C-2), 80.8 (C-4), 74.9 
(PhCH2), 73.7, 71.7 (OCH2), 69.2 (C-5), 55.4, 55.2 (OCH3), 31.7-22.6 (CH2), 14.0 (CH3), 8.1 
(C-6); ESI MS: m/z: 631.3 [M + K]
+
, 615.4 [M + Na]
+
. Anal. Calcd for C27H45IO6: C, 54.73; H, 
7.65; found: C, 54.88; H, 7.71. 
Methyl 6-(2-tert-Butoxycarbonylaminoethylthio)-2,3-di-O-hexyl-4-O-p-methoxybenzyl--D-
glucopyranoside (21). To a suspension of 19 (0.69 g, 1.16 mmol) and Cs2CO3 (0.53 g, 1.62 
mmol) in dry DMF (10 mL), tert-butyl (2-mercaptoethyl)carbamate (0.27 mL, 1.62 mmol,) was 
added and the reaction mixture was stirred at 60 ºC, under Ar atmosphere, for 24 hours. The 
mixture was concentrated, EtOAc (25 mL) and water (25 mL) were added then the organic layer 
was separated, washed with H2O (3 x 25 mL), dried (MgSO4), filtered, concentrated and the 
residue was purified by column chromatography (1:61:4 EtOAc-cyclohexane). Yield 99% 
(0.74 g, 1.15 mmol). Rf = 0.17 (1:6 EtOAc-cyclohexane); []D = +64.2 (c 1.0, DCM); IR: max= 
1714  cm
-1
; 
1
H NMR (300 MHz, CDCl3):   = 7.24, 6.87 (2 d, 4 H, 
3
JH,H = 8.7 Hz, aromatics), 
4.98 (bs, 1 H, NH), 4.84 (d, 1 H, 
2
JHa,Hb = 10.8 Hz, PhCHa), 4.74 (d, 1 H, J1,2 = 3.4 Hz, H-1), 
4.54 (d, 1 H, PhCHb),  3.85 (m, 1 H, OCH2), 3.79 (s, 3 H, PhOCH3), 3.74-3.52 (m, 3 H, OCH2), 
3.71 (m, 1 H, H-5), 3.64 (t, 1 H, J2,3 = J3,4 = 9.3 Hz, H-3), 3.40 (s, 3 H, OCH3), 3.31-3.25 (m, 4 
H, H-2, H-4, CH2N), 2.84 (dd, 1 H, J6a,6b = 13.9 Hz, J5,6a = 2.6 Hz, H-6a), 2.71 (t, 2 H, 
3
JH,H = 6.4 
Hz, CH2S), 2.57 (dd, 1 H, J5,6b = 7.5 Hz,  H6b), 1.65-1.55 (m, 4 H, CH2), 1.44 (s, 9 H, CMe3), 
1.36-1.24 (m, 12 H, CH2), 0.88, 0.87 (2 t, 6 H, 
3
JH,H = 6.6 Hz, CH3);
13
C NMR (75.5 MHz, 
CDCl3):   = 159.3 (CO), 130.5-113.9 (Ph), 97.8 (C-1), 81.6 (C-3), 80.9 (C-2), 80.1 (C-4), 79.3 
(CMe3), 74.7 (CH2Ph), 73.7, 71.7 (2 CH2), 70.7 (C-5), 55.3, 55.0 (2 OCH3), 39.7 (CH2N), 33.6 
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(C-6), 33.5 (CH2S), 31.7-29.6 (CH2), 28.4 (CMe3), 26.9-22.6 (CH2), 14.0 (CH3); ESI MS: m/z: 
664 [M + Na]
+
, 680 [M + K]
+
. Anal. Calcd for C34H59NO8S: C, 63.62; H, 9.26; N, 2.18; S, 5.00; 
found: C, 63.73; H, 9.21; N, 1.98; S, 4.86. 
Methyl 6-(2-Aminoethylthio)-2,3-di-O-hexyl--D-glucopyranoside Hydrochloride (3). 
Treatment of 21 (0.35 g, 0.55 mmol) with 1:1 TFA-DCM (2 mL) and freeze-drying from 10:1 
H2O/0.1 N HCl solution afforded 3.. Yield quant. (0.20 g, 0.54 mmol). Rf = 0.45 (45:5:3 EtOAc-
EtOH-H2O); []D = +74.4 (c 1.0, MeOH); IR: max= 3404, 1109 cm
-1
; 
1
H NMR (300 MHz, 
CD3OD):  = 4.80 (d, 1 H, J1,2 = 3.9 Hz, H-1), 3.74 (t, 1 H, 
3
JH,H = 6.8 Hz, OCH2), 3.67-3.51 (m, 
4 H, H-5, OCH2), 3.42 (s, 3 H, OCH3),  3.40 (t, 1 H, J2,3 = J3,4 = 9.3 Hz, H-3), 3.29 (t, 1 H, J4,5 = 
9.3 Hz, H-4), 3.23 (dd, 1 H, H-2), 3.16 (t, 2 H, 
3
JH,H = 6.8 Hz, CH2N), 2.99 (dd, 1 H, J6a,6b = 14.4 
Hz, J5,6a = 2.3 Hz, H-6a), 2.90 (m, 2 H, CH2S), 2.72 (dd, 1H, J5,6a = 8.0 Hz, H6b), 1.60-1.52 (m, 
4 H, CH2), 1.42-1.31 (bs, 12 H, CH2), 0.90, 0.89 (2 t, 6 H, 
3
JH,H = 6.6 Hz, CH3); 
13
C NMR (75.5 
MHz, CD3OD):   = 99.1 (C-1), 82.6 (C-3), 81.6 (C-2), 74.6 (OCH2), 74.0 (C-4),  73.4 (C-5), 
72.2 (OCH2), 55.5 (OCH3), 40.0 (CH2N), 34.2 (C-6), 33.0-31.1 (CH2), 31.1 (CH2S), 26.9, 26.8, 
23.7 (CH2), 14.4 (CH3); ESI MS: m/z: 422.5 [M - Cl]
+
. Anal. Calcd for C21H43NO5S·HCl: calcd. 
C, 55.06; H, 9.68; N, 3.06; S, 7.00; found: C, 54.87; H, 9.45; N, 2.79; S, 6.78.  
Methyl 2,3-di-O-Tetradecyl--D-glucopyranoside (18). Methyl 4,6-O-(4-
methoxybenzylidene)-2,3-di-O-tetradecyl--D-glucopyranoside (0.70 g, 0.98 mmol) was 
dissolved in a mixture of Et2O-DCM (2:1, 15 mL), under Ar atmosphere. AlCl3 (0.81 g, 6.06 
mmol) in Et2O (15 mL) were added dropwise and the resulting mixture was refluxed for 4 h. 
After cooling to rt, EtOAc (150 mL) and H2O (150 mL) were added and the layers separated. 
The organic layer was washed with brine (3 × 100 mL), dried (Mg2SO4) and evaporated. Column 
chromatography of the residue (1:1 EtOAc-cyclohexane) afforded 18. Yield 87% (0.50 mg, 0.85 
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mmol); Rf = 0.47 (1:1 EtOAc-cyclohexane); []D = +24.7 (c 1.0, DCM); IR: max 3362, 2953, 
1468 cm
-1
; 
1
H NMR (300 MHz, CDCl3):  = 4.78 (d, 1 H, J1,2 = 3.5 Hz, H-1), 3.94-3.43 (m, 9 H, 
H-3, H,4 H-5, H-6a, H-6b, 2 OCH2), 3.41 (s, 3 H, OCH3), 3.26 (dd, 1 H, J2,3 = 9.2 Hz, H-2), 
1.69-1.48 (m, 4 H, CH2), 1.25 (bs, 44 H, CH2), 0.87 (t, 6 H, 
3
JH,H = 6.9 Hz, CH3);
13
C NMR (75.5 
MHz, CDCl3):  = 98.1 (C-1), 81.0, 80.6 (C-2, C-3), 73.6 (C-4), 71.3, 70.7 (OCH2), 70.5 (C-5), 
62.5 (C-6), 55.2 (OCH3), 31.9-22.6 (CH2), 14.1 (CH3); ESI MS: m/z: 625.6 [M + K]
+
, 609.8 [M 
+ Na]
+
. Anal. Calcd for C35H70O6: C, 71.62; H, 12.02; found: C, 71.38; H, 11.76. 
Methyl 2,3-di-O-Tetradecyl-6-deoxy-6-iodo--D-glucopyranoside (20). To a solution of 18 
(0.49 g, 0.84 mmol) in toluene (17 mL) triphenylphosphine (0.33 g, 1.26 mmol) and imidazole 
(0.17 g, 2.52 mmol) were added. Iodine (0.33 g, 1.17 mmol) was added in portions and the 
resulting solution was stirred at 70 ºC for 3 h. After cooling at rt, NaHCO3 sat. (20 mL) was 
added and the mixture was stirred for 5 min. Additional iodine was added up to turn brown the 
organic phase and the mixture was stirred for 10 min. Then, aqueous 10% Na2S2O3 was added to 
remove the iodine excess. The organic layer was separated, washed with H2O (3 x 20 mL), dried 
(MgSO4), filtered, concentrated, and purified by column chromatography (1:9 EtOAc-
cyclohexane). Yield 91% (0.03 g, 0.76 mmol; Rf = 0.30 (1:9 EtOAc-cyclohexane); []D = +44.1 
(c 1.0, DCM); IR :max= 1041, 722 cm
-1
; 
1
H NMR (300 MHz, CDCl3):  = 4.81 (d, 1 H, J1,2 = 3.6 
Hz, H-1), 3.91 (m, 1 H, OCH2), 3.66-3.49 (m, 5 H, H-6a, OCH2, H-3), 3.47 (s, 3 H, OCH3), 3.45 
(ddd, 1 H, J4,5 = 9.2 Hz, J5,6a = 6.8 Hz, J5,6b = 2.2 Hz, H-5), 3.31 (m, 1 H, H-4) 3.29 (dd, 1 H, J2,3 
= 10.0 Hz, H-2), 3.26 (dd, 1 H, J6a,6b = 11.2 Hz, H-6b), 2.41 (d, 1 H, J4,OH = 2.3 Hz, OH-4), 1.61-
1.54 (m, 4 H, CH2), 1.25 (bs, 44 H, CH2), 0.88 (t, 6 H, 
3
JH,H = 6.9 Hz, CH3);
13
C NMR (75.5 
MHz, CDCl3):  = 98.2 (C-1), 80.7, 80.5 (C-2, C-3), 73.8 (C-4), 73.6, 71.2 (OCH2), 69.7 (C-5), 
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55.5 (OCH3), 31.9-22.7 (CH2), 14.1 (CH3), 7.2 (C-6); ESI MS: m/z: 735.6 [M + K]
+
, 719.7 [M + 
Na]
+
. Anal. Calcd for C35H69IO5: C, 60.33; H, 9.98. Found: C, 59.89; H, 9.72. 
Methyl 6-(2-tert-Butoxycarbonylaminoethylthio)-2,3-di-O-tetradecyl--D-glucopyranoside 
(22). To a suspension of 20 (0.53 g, 0.77 mmol) and Cs2CO3 (0.35 g, 1.07 mmol) in DMF (7 
mL), tert-butyl (2-mercaptoethyl)carbamate (0.18 mL, 1.07 mmol) was added and the reaction 
mixture was stirred at 60 ºC, under Ar atmosphere for 24 h. The mixture was concentrated then 
EtOAc (20 mL) and H2O (20 mL) were added and the organic layer was separated, washed with 
H2O (3 x 20 mL), dried (MgSO4), filtered, and concentrated. The residue was purified by column 
chromatography (1:3 EtOAc-cyclohexane) affording 22. Yield 95% (0.54 g,0.73 mmol); Rf = 
0.40 (1:3 EtOAc-cyclohexane); []D = +50.4 (c 1.0, DCM); IR: max= 3631, 1698cm
-1
; 
1
H NMR 
(300 MHz, CDCl3):  = 4.99 (bs, 1 H, NH), 4.77 (d, 1 H, J1,2 = 3.6 Hz, H-1), 3.90 (m, 1 H, 
OCH2), 3.72 (ddd, 1 H, J4,5 = 9.3 Hz, J5,6a = 7.5 Hz, J5,6b = 2.6 Hz, H-5), 3.64-3.46 (m, 3 H, 
OCH2), 3.48 (t, 1 H, J2,3 = J3,4 =  9.3 Hz, H-3), 3.43 (s, 3 H, OCH3), 3.36 (t, 1 H, H-4), 3.31 (m, 2 
H, CH2N), 3.27 (dd, 1 H, H-2), 2.98 (dd, 1 H, J6a,6b = 14.1 Hz, H-6a), 2.71 (m, 3 H, H6b, CH2S), 
2.63 (bs, 1 H, OH-4), 1.65-1.50 (m, 4 H, CH2), 1.43 (s, 9 H, CMe3), 1.24 (bs, 44 H, CH2), 0.87 (t, 
6 H, 
3
JH,H = 7.0 Hz, CH3); 
13
C NMR (75.5 MHz, CDCl3):   = 156 (CO), 97.9 (C-1), 80.9 (C-3), 
80.6 (C-2), 79.4 (CMe3), 73.5 (OCH2), 72.4 (C-4),  71.2 (OCH2), 71.0 (C-5), 55.2 (OCH3), 39.6 
(CH2N), 33.5 (C-6), 33.4 (CH2S), 31.8-29.3 (CH2), 28.4 (CMe3), 26.1-22.6 (CH2), 14.0 (CH3); 
ESI MS: m/z: 784.7 [M + K]
+
, 768.8 [M + Na]
+
. Anal. Calcd for C42H83NO7S: C, 67.60; H, 
11.21; N, 1.88; S, 4.30. Found: C, 67.45; H, 10.90; N, 1.62; S, 4.24. 
Methyl 6-(2-Aminoethylthio)-2,3-di-O-tetradecyl--D-glucopyranoside Hydrochloride (4). 
Treatment of 22 (0.25 g, 0.33 mmol) with 1:1 TFA-DCM (2 mL) and freeze-drying from 10:1 
H2O/0.1 N HCl solution afforded 4. Yield quant (0.22 g, , 0.33 mmol). Column chromatography 
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of the residue (4:1 EtOAc-cyclohexaneEtOAc45:5:3 EtOAc-EtOH-H2O). Rf = 0.25 (45:5:3 
EtOAc-EtOH-H2O); []D = +41.3 (c 0.9, 9:1 DCM-MeOH); IR: max= 3406, 722 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3):  = 8.11 (bs, 2 H, NH2HCl), 4.78 (d, 1 H, J1,2 = 3.2 Hz, H-1), 3.87 (m, 1 H, 
OCH2), 3.74 (ddd, 1 H, J4,5 = 9.4 Hz, J5,6b = 6.7 Hz, J5,6a = 2.7 Hz, H-5), 3.66-3.54 (m, 3 H, 
OCH2), 3.49 (t, 1 H, J2,3 = J3,4 = 8.9 Hz, H-3), 3.42 (s, 3 H, OCH3), 3.38 (t, 1 H, H-4), 3.27 (dd, 1 
H, H-2), 3.18 (t, 2 H, 
3
JH,H = 6.2 Hz, CH2N), 2.97 (dd, 1 H, J6a,6b = 14.2 Hz, H-6a), 2.90 (m, 2 H, 
CH2S), 2.74 (dd, 1H, H6b), 1.60-1.54 (m, 4 H, CH2), 1.25 (bs, 44 H, CH2), 0.87 (t, 6 H, 
3
JH,H = 
6.9.0 Hz, CH3);
13
C NMR (75.5 MHz, CDCl3):  = 97.9 (C-1), 80.9 (C-3), 80.5 (C-2), 73.7 
(OCH2), 72.1 (C-4),  71.3 (OCH2), 70.7 (C-5), 55.2 (OCH3), 38.7 (CH2N), 33.2 (C-6), 31.9 
(CH2), 30.3 (CH2S), 30.3-22.7 (CH2), 14.1 (CH3); ESI MS: m/z: 646.7 [M - HCl]
+
. Anal. Calcd 
for C37H75NO5S·HCl·2H2O: C, 61.85; H, 11.22; N, 1.95; S, 4.46. Found: C, 61.79; H, 11.03; N, 
2.01; S, 4.43. 
Methyl 6-(2-tert-Butoxycarbonylaminoethylthio)-2,3,4-tri-O-hexanoyl--D-glucopyranoside 
(24). To a solution of 23 (0.49 g, 0.83 mmol) in dry DMF (7.5 mL), Cs2CO3 (0.38 g, 0.16 mmol) 
and tert-butyl N-(2-mercaptoethyl)carbamate (196 L, 1.16 mmol) were added, under Ar 
atmosphere, and the reaction mixture was stirred at 60 ºC for 48 h. The reaction mixture was 
concentrated and the crude product was dissolved in DCM (10 mL) and washed with H2O (2 x 
15 mL). The organic phase was dried (MgSO4), filtered, concentrated, and the residue was 
purified by flash column chromatography (1:4 EtOAc-cyclohexane). Yield 85% (0.45 mg, 0.70 
mmol). Rf = 0.38 (1:3 EtOAc-cyclohexane); []D = +62.1 (c 1.0, DCM); IR: max = 2958, 1747, 
1701cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ = 5.46 (t, 1 H, J2,3 = J3,4= 10 Hz, H-3), 4.95 (t, 1 H, 
J4,5= 10.0 Hz, H-4), 3.41 (s, 3 H, OCH3), 4.90 (d, 1 H, J1,2 = 3.7 Hz, H-1), 4.83 (dd, 1 H, H-2), 
3.90 (dt, 1 H, J5,6b = 8.0 Hz,  H-5), 3.27 (q, 2 H, JH,H = 6.0 Hz, CH2N), 2.8-2.5 (m, 4 H, CH2S, H-
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6ª, H-6b), 2.52 (m, 2 H, H-6ª, H-6b), 2.31 (m, 6 H, H-2Hex,), 1.54 (m, 6 H, H-3Hex), 1.41 (s, 9 H, 
CMe3), 1.25 (m, 12 H, H-4Hex, H-5Hex), 0.86 (t, 9 H,
 
H-6Hex); 
13
C NMR (75.5 MHz, CDCl3): δ = 
172.9-172.0 (CO ester), 155.7 (CO carbamate) 96.7 (C-1), 71.5 (C-4), 70.9 (C-2), 69.3 (C-3), 
69.9 (C-5), 55.1 (OMe), 39.58 (CH2N), 33.7 (CH2S), 33.0 (C-6), 34.0 (C-2Hex), 24.5 (C-3Hex), 
28.2 (CMe3), 22.1 (C-5Hex), 13.6 (C-6Hex); ESI MS: m/z = 670.4 [M + Na]
+
. Anal. Calcd for 
C32H57NO10S: C, 59.32; H, 8.87; N, 2.16; S, 4.95 found: C, 59.45; H, 8.93; N, 2.31; S, 4.71. 
Methyl 6-(2-Aminoethylthio)-2,3,4-tri-O-hexanoyl--D-glucopyranoside Hydrochloride 
(25). Treatment of 24 (0.29 g, 0.44 mmol) with 1:1 TFA-DCM (6 mL) and freeze-drying from 
10:1 H2O/0.1 N HCl solution afforded 25. Yield quant. (0.27 mg, 0.44 mmol) ; []D =+72.0 (c 
0.7, EtOAc); IR: max = 2962, 1749 cm
-1
;
 1
H NMR (300 MHz, CD3OD): δ = 8.05 (bs, 3 H, NH3), 
5.28 (t, 1 H J2,3 = 9.7 Hz, J3,4 = 9.7 Hz, H-3), 4.94 (t, 1 H, J4,5 = 9.7 Hz, H-4), 4.88 (m, 1 H, J1,2 = 
3.8 Hz, H-1), 4.82 (dd, 1 H, H-2), 3.8 (m, 1 H, H-5), 3.34 (s, 1 H, OCH3), 2.93 (bs, 2 H, CH2N), 
2.78 (m, 2 H, CH2S), 2.73 (dd, 1 H, J6a,6b = 14.0 Hz, J5,6a = 2.7, H-6ª), 2.62 (dd, 1 H, J5,6b = 7.7 
Hz, H-6b), 2.26 (m, 6 H, H-2Hex), 1.44 (m, 6 H, H-3Hex), 1.21 (m, 12 H, H-4Hex, H-5Hex), 0.82 (t, 
9 H,
 
H-6Hex); 
13
C NMR (75.5 MHz, CD3OD): δ = 172-171 (CO), 95.98 (C-1), 71.2 (C-4), 70.6 
(C-2), 69.4 (C-3), 69.1 (C-5), 55.1 (OMe), 39.1 (CH2N), 32.5 (C-6), 30.5 (CH2S), 33.1 (C-2Hex), 
31.1 (C-4Hex), 24 (C-3Hex), 22.1(C-2Hex), 14.4 (C-6Hex); ESIMS: m/z = 548.3 [M + H]
+
. Anal. 
Calcd for C27H50ClNO8S·HCl: C, 55.51; H, 8.63; N, 2.40; S, 5.49; found: C, 55.37; H, 8.62; N, 
2.26; S, 5.27. 
Methyl 6-(2-(N’-(2-(N,N-di-(2-(N-tert-Butoxycarbonylamino)ethyl)amino)ethyl)thioureido)-
ethylthio)-2,3,4-tri-O-hexanoyl--D-glucopyranoside (27). To a solution of 25 (0.12 g, 0.20 
mmol) and Et3N (56 L, 0.4 mmol) in DCM (6 mL), 2-[N,N-bis(2-(N-tert-
butoxyaminocarbonyl)ethylamino]ethyl isothiocyanate (0.09 g, 0.24 mmol) was added and the 
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reaction mixture was stirred, under Ar atmosphere, at rt for 48 h. The reaction mixture was 
washed with aqueous diluted HCl (2 x 20 mL), dried (MgSO4), filtered and concentrated. The 
residue was purified by column chromatography (1:1→ 3:1 EtOAc-cyclohexane). Yield 50% 
(0.08 g, 0.10 mmol). Rf = 0.2 (1:1 EtOAc-cyclohexane); []D = + 71.6 (c 1.0, DCM); IR: max = 
2959, 1748, 1685 cm
-1
;
 1
H NMR (300 MHz, CDCl3): δ = 7.46, 6.96 (2 bs, 2 H, NHCS), 5.46 (t, 1 
H, J2,3 = J3,4 = 9.8 Hz, H-3), 4.96 (t, 1 H, J4,5 = 9.8 Hz, H-4), 4.90 (d, 1 H, J1,2 = 3.5 Hz, H-1), 
4.88 (bs, 2 H, NHBoc), 4.84 (dd, 1 H, H-2), 3.93 (bd, 1 H, H-5), 3.77 (q, 2 H, NHCH2CH2N), 
3.52 (bs, 2 H, SCH2CH2N), 3.42 (s, 3 H, OCH3), 3.11 (q, 4 H, NCH2CH2NHBoc), 2.82 (t, 2 H, 
JH,H = 7.0 Hz, NHCH2CH2N), 2.77-2.56 (m, 4 H, H-6a, H-6b, SCH2), 2.50 (bs, 4 H, 
NCH2CH2NHBoc), 2.37-2.1 (m, 6 H, H-2Hex), 1.57 (m, 6 H, JH,H = 7 Hz, H-3Hex), 1.43 (s, 9 H, 
CMe3), 1.27 (m, 12 H, H-4Hex, H-5Hex), 0.87 (t, 9 H,
 
H-6Hex); 
13
C NMR (75.5 MHz, CDCl3): δ = 
182.1 (CS), 172.0-171.0 (CO ester), 155.2 (CO carbamate), 96.6 (C-1), 70.9 (C-4), 70.1 (C-2), 
69.9 (C-5), 69.6 (C-3), 55.8 (NCH2CH2NHBoc), 55.5 (OMe), 54.0 (SCH2), 44.1 (NHCH2CH2N), 
42.4 (SCH2CH2N), 39.4 (NCH2CH2NHBoc), 33.1 (C-6), 32.6 (NHCH2CH2N), 34.1 (C-2Hex), 
31.2 (C-5 Hex), 28.4 (CMe3) 24.5 (C-3Hex), 22.1 (C-5Hex), 13.9 (C-6Hex); ESI MS: m/z = 958.6 [M 
+ Na]
+
 Anal. Calcd for C44H81N5O12S2: C, 56.44; H, 8.72; N, 7.48; S, 6.85; found: C, 56.61; H, 
8.89; N, 7.21; S, 6.60.  
Methyl 6-(2-(N’-(2-(N,N-Bis-(2-aminoethyl)amino)ethyl)thioureido)ethylthio)-2,3,4-tri-O-
hexanoyl--D-glucopyranoside Trihydrochloride (5). Treatment of 27 (0.15 g, 0.16 mmol) 
with 1:1 TFA-DCM (2 mL) and freeze-drying from 10:1 H2O/0.1 N HCl solution afforded 5. 
Yield quant. (0.13 g, 0.16 mmol). []D = + 46.8 (c 0.85, MeOH); IR: max = 2958, 1747, 1675 
cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ = 7.98 (bs, 4 H, NHCS, NH2HCl), 7.60 (bs, 1 H, NHCS), 
5.47 (t, J3,4 = J2,3= 9.5 Hz, 1 H, H-3), 4.99 (t, 1 H, J4,5 = 9.5 Hz, H-4), 4.91 (dd, 1 H, J1,2 = 4 Hz,  
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H-1), 4.85 (dd, 1 H, H-2), 3.96 (td, 1 H, J5,6b = 7.3 Hz, J5,6a = 2.4 Hz, H-5), 3.73 (bs, 2 H, 
SCH2CH2NHCS), 3.68 (bs, 2 H, NHCSCH2CH2N), 3.41 (s, 3 H, OCH3), 3.11 (bs, 4 H, 
CH2NH3Cl), 2.84 (bs, 6 H, CH2CH2NH3Cl, SCH2CH2NHCS), 2.75 (m, 3 H, H-6a, 
NHCSCH2CH2N), 2.66 (dd, 1 H, J6a,6b = 13.8 Hz, H-6b), 2.32-2.19 (m, 6 H, H-2Hex), 1.55 (m, 6 
H, H-3Hex), 1.27 (m, 12 H, H-4Hex, H-5Hex), 0.87 (m, 9 H,
 
H-6Hex); 
13
C NMR (75 MHz, CDCl3): 
173.1, 173.0, 172.6 (CO), 96.6 (C-1), 71.2 (C-4), 70.8 (C-2), 69.6 (C-3), 69.1 (C-5), 55.4 
(OCH3), 53.4 (NHCSCH2CH2N), 52.0 (CH2CH2NH2HCl), 43.1 (SCH2CH2NHCS), 41.7 
(NHCSCH2CH2N), 37.6 (CH2NH3Cl), 34.1, 34.0 (C-2Hex), 33.0 (C-6), 32.7 (SCH2CH2NHCS), 
31.2, 31.1 (C-4Hex), 24.5, 24.4 (C-3Hex), 22.2 (C-5Hex), 13.8 (C-6Hex); ESI MS: m/z = 736.4 [M]
+
. 
Anal. Calcd for C34H65N5O8S2·3HCl: C, 48.30; H, 8.11; N, 8.28; S, 7.58; found: C, 48.24; H, 
8.39; N, 8.15; S, 7.41.  
Methyl 6-(4-(2,2-Bis-tert-butoxycarbonylamino)ethylaminomethyl)-1H-1,2,3-triazol-1-yl-6-
deoxy)-2,3,4-tri-O-hexanoyl--D-glucopyranoside (29). To a solution of 28 (0.20 g, 0.39 
mmol) and 3-bis[2-tert-butoxycarbonylamino)ethyl]propargylamine (0.29 g, 0.85 mmol) in H2O-
t
BuOH 9:1 (15 mL), the Cu-supported catalyst Si-BPA·Cu
+ 
(0.02g) was added and the reaction 
mixture was refluxed for 36 h at 85 ºC. The catalyst was filtered and the solvent was removed. 
The residue was purified by column chromatography (1:1→2:1 EtOAc-cyclohexane). Yield 78% 
(0.25 g, 0.30 mmol). Rf = 0.61 (9:1 DCM-MeOH); []D = +50.5 (c 1.0, DCM); IR: max = 2957, 
2359, 1748, 1703, 734 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ = 7.59 (s, 1 H, =CH), 5.49 (t, 1 H, 
J2,3 = J3,4 = 10.3 Hz , H-3),  4.89 (bs, 2 H, NHBoc), 4.87 (d, 1 H, J1,2 = 3.5 Hz, H-1), 4.85 (t, 1 H, 
J4,5 = 10.3 Hz, H-4), 4.81 (dd, 1 H, H-2), 4.53 (dd, 1 H, J6a,6b = 14.0 Hz, J5,6a = 2.6 Hz, H-6a), 
4.29 (dd, 1 H, J5,6b = 9.0 Hz, H-6b), 4.17 (ddd, 1 H, H-5), 3.80 (m, 2 H, CH2-triazole), 3.18 (bs, 4 
H, CH2NHBoc), 3.07 (s, 3 H, OCH3), 2.55 (t, 4 H, CH2CH2NHBoc), 2.27 (m, 6 H, H-2Hex), 1.58 
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(s, 9 H, CMe3), 1.44 (m, 6 H, H-3Hex), 1.30 (m, 12 H, H-4Hex,H-5Hex), 0.89 (m, 9 H, H-6Hex); 
13
C 
NMR (75.5 MHz, CDCl3): δ = 173.9, 173.5, 173,1 (CO ester), 156.2 (CO carbamate), 144.1 (C-4 
triazole), 124.3 (C-5 triazole), 91.4 (C-1), 78.1 (CMe3), 70.6 (C-2), 69.8 (C-4), 69.3 (C-3), 68.0 
(C-5), 53.1 (CH2CH2NHBoc ), 50.6 (C-6), 48.3 (CH2 triazole), 38.4 (CH2NHBoc), 34.1 (C-2Hex), 
31.7 (C-4Hex), 28.5 (CMe3), 24.6 (C-3Hex), 22.6 (C-5Hex), 13.8 (C-6Hex); ESI MS: m/z = 877.5 [M 
+ Na]
+
. Anal. Calcd for C42H74N6O12: calcd. C, 59.00; H, 8.72; N, 9.83; found: C, 59.09; H, 8.77; 
N, 9.64. 
Methyl 6-Deoxy-6-(4-(2,2-diaminoethylaminomethyl)-1H-1,2,3-triazol-1-yl)-2,3,4-tri-O-
hexanoyl--D-glucopyranoside Dihydrochloride (30). Treatment of 29 (0.42 g, 0.49 mmol) 
with 1:1 TFA-DCM (5 mL) and freeze-drying from 10:1 H2O/0.1 N HCl solution afforded 30. 
Yield quant.(0.35 g, 0.49 mmol). []D = +38.1 (c 1.0, MeOH); IR: max = 2957, 1748, 1675 cm
-1
;
 
1
H NMR (300 MHz, CD3OD): δ = 8.07 (s, 1 H, =CH), 5.42 (t, 1 H, J2,3 =  J3,4 = 9.5 Hz, H-3), 
4.93 (d, 1 H, J1,2 = 3.5 Hz, H-1), 4.82 (dd, 1 H, H-2), 4.76  (t, 1 H, J4,5 = 9.5 Hz, H-4), 4.64 (m, 2 
H, H-6a, H-6b), 4.27 (ddd, 1 H, J5,6a = 3.7 Hz, J5,6b = 6.0 Hz, H-5), 3.92 (s, 2 H, CH2 triazole), 
3.26 (s, 3 H, OMe), 3.16 (t, 4 H, JH,H = 6.4 Hz, CH2CH2NH2), 2.82 (t, 4 H, CH2CH2NH2), 2.48-
2.15 (m, 6 H, H-2Hex), 1.58 (m, 6 H, H-3Hex), 1.33 (m, 12 H, H-4Hex, H-5Hex), 0.92 (m, 9 H, H-
6Hex); 
13
C NMR (75.5 MHz, CD3OD): δ = 174.2-173.9 (CO), 143.8 (C-4 triazole), 126.9 (C-5 
triazole), 98.6 (C-1), 71.8 (C-2), 70.7 (C-3), 70.3 (C-4), 68.9 (C-5), 56.0 (OCH3), 52.0  
(CH2CH2NH2), 51.6 (C-6), 47.4 (CH2 triazole), 38.2 (CH2CH2NH2), 34.9, 34.8, 34.7 (C-2Hex), 
32.4 , 32.2 (C-4Hex), 25.6, 25.5 (C-3Hex), 23.4 (C-5Hex), 14.2 (C-6Hex); ESI MS: m/z = 831.3 [M + 
TFA + Cl + Cu]
+
; 717.3 [M + Cu + Cl ]
+
; Anal. Calcd for C32H59N6O8·2HCl: calcd. C, 52.81; H, 
8.31; N, 11.55; found: C, 52.69; H, 8.1; N, 11.72. 
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Dendritic Boc-protected Diminoethyl-bis(thiourea) Glucopyranoside Derivative 31. To a 
solution of 30 (0.20 g, 0.27 mmol) and Et3N (115 L, 0.82 mmol) in DCM (12 mL), tert-butyl 
N-(2-isothiocyanoethyl)carbamate (0.17 mg, 0.82 mmol) was added and the mixture was stirred 
overnight at rt. The reaction mixture was washed with aqueous diluted HCl (3 x 10 mL) and the 
organic phase was dried (MgSO4), filtered, and concentrated. The residue was purified by 
column chromatography (3:1 EtOAc-cyclohexane→20:1 DCM-MeOH). Yield 52% (0.15 g, 0.14 
mmol). Rf = 0.44 (9:1 DCM-MeOH); []D = +31.7 (c 1.0, DCM); IR: max = 2959, 1750, 1698, 
736 cm
-1
;
 
UV (DCM): 248 nm (mM 47.8). 
1
H NMR (300 MHz, CDCl3): δ = 7.62 (s, 1 H, =CH), 
7.18, 6.94 (bs, 4 H, NHCS), 5.49 (t, 1 H, J2,3 = J3,4 = 9.5 Hz , H-3), 5.38 (bs, 2 H, NHBoc), 4.82 
(d, 1 H, J1,2 = 3.5 Hz, H-1), 4.80 (t, 1 H, J4,5 = 9.5 Hz, H-4),  4.80 (dd, 1 H, H-2), 4.53 (dd, 1 H, 
J6a,6b = 14.5 Hz,  J5,6a = 2.6 Hz, H-6a), 4.37 (dd, 1 H, J5,6b = 8.0 Hz, H-6b), 4.17 (ddd, 1 H, H-5), 
3.79 (s, 2 H, CH2 triazole), 3.62 (bs, 4 H, CH2CH2NHBoc), 3.54 (bs, 4 H, NCH2CH2NHCS), 
3.31 (m, 4 H, CH2NHBoc), 3.12 (s, 1 H, OCH3), 2.69 (bs, 4 H, NCH2CH2NHCS), 2.42-2.13 (m, 
6 H, H-2Hex), 1.55 (m, 6 H, H-3Hex), 1.42 (s, 18 H, CMe3), 1.26 (m, 12 H, H-4Hex, H-5Hex), 0.87 
(t, 9 H,  H-6Hex); 
13
C NMR (75.5 MHz, CDCl3): δ = 182.7 (CS), 173.0-172.5 (CO ester), 155.5 
(CO carbamate), 144.5 (C-4 triazole), 124.4 (C-5 triazole), 96.7 (C-1), 79.8 (CMe3), 70.2 (C-2), 
69.6 (C-4), 69.2 (C-3), 67.8 (C-5), 55.4 (OMe), 52.4 (NCH2CH2NHCS), 50.7 (C-6), 48.0 (CH2 
triazole), 44.6 (CH2CH2NHBoc), 42.1 (NCH2CH2NHCS), 40.1 (CH2NHBoc), 34.3 (C-2Hex), 30.8 
(C-4Hex), 28.1 (CMe3), 24.2 (C-3Hex), 22.6 (C-5Hex), 14.1 (C-6Hex); ESI MS: m/z = 1081.5 [M + 
Na]
+
. Anal. Calcd for C48H86N10O12S2: calcd. C, 54.42; H, 8.18; N, 13.22; S, 6.05; found: C, 
54.37; H, 7.98; N, 13.28; S, 5.85 
Dendritic Diminoethyl-bis(thiourea) Glucopyranoside Dihydrochloride Derivative (6). 
Treatment of 31 (0.12 g, 0.12 mmol) with 1:1 TFA-DCM (2 mL) and freeze-drying from 10:1 
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H2O/0.1 N HCl solution afforded 6. Yield 91%(0.10 g, 0.11 mmol). []D = +47.7 (c 1.0, MeOH); 
IR: max = 2955, 1748, 1676 cm
-1
; UV (MeOH): 244 nm (mM 29.1); 
1
H NMR (300 MHz, 
CD3OD): δ = 8.43 (s, 1 H, =CH), 5.43 (t, 1 H, J2,3 = J3,4 = 9.7 Hz, H-3), 4.97 (d, 1 H,
 
J1,2 = 3.5 
Hz, H-1), 4.90 (dd, 1 H, H-2), 4.82 (t, 1 H, J4,5 = 9.7 Hz, H-4), 4.77 (m, 2 H, CH2 triazole), 4.70 
(m, 2 H, H-6a, H-6b), 4.27 (ddd, 1 H, J5,6a = 3.7 Hz, J5,6b = 5.6 Hz, H-5), 4.06 (bs, 4 H, 
CH2CH2NH2), 3.87 (t, 4 H, 
3
JH,H = 5.8 Hz, NCH2CH2NHCS), 3.52 (t, 4 H, 
3
JH,H = 5.8 Hz, 
CH2NH2), 3.25 (s, 3 H, OCH3), 3.21 (t, 4 H, JH,H = 6.0 Hz, NCH2CH2NHCS), 2.50-2.15 (m, 6 H, 
H-2Hex), 1.56 (m, 6 H, H-3Hex), 1.31 (m, 12 H, H-4Hex, H-5Hex), 0.91 (m, 9 H, H-6Hex); 
13
C NMR 
(75.5 MHz, CD3OD): δ = 184.1 (CS), 174.3-173.9 (CO), 137.2 (C-4 triazole), 130.1 (C-5 
triazole), 98.2 (C-1), 71.8 (C-2), 71.2 (C-3), 70.5 (C-4), 68.7 (C-5), 56.2 (OMe), 54.4 (CH2NH2), 
51.4 (C-6), 48.4 (CH2 triazole), 42.2 (CH2CH2NH2), 40.4 (NCH2CH2NHCS), 40.0 (CH2NH2), 
34.4 (C-2Hex), 32.0 (C-4Hex), 25.2 (C-3Hex), 22.8 (C-5Hex), 14.0 (C-6Hex). ESI MS: m/z = 859.5 [M 
+ Na]
+
; 921.4 [M + Cu]
+
. Anal. Calcd for C38H72Cl2N10O8S2: calcd. C, 48.97; H, 7.79; N, 15.03; 
S, 6.88 found: C, 48.71; H, 77.40; N, 15.23; S, 6.65. 
2,3,4,2’,3’,4’-Hexa-O-hexyl-6,6’-di-O-trityl-’-trehalose (33). To a solution of 32 (1.00 g, 
1.21 mmol) in dry DMF (11 mL), NaH (871 mg, 21.78 mmol) was added and the mixture was 
stirred at 0 ºC for 10 min. 1-Bromohexane (3.06 mL, 21.78 mmol) was added dropwise under Ar 
atmosphere and the mixture was stirred overnight at rt. The reaction was quenched with MeOH 
(5 mL) and stirred for 10 min. The solvents were removed and the resulting residue was 
suspended in DCM (50 mL), washed with H2O (3 x 15 mL) and the organic layer was separated, 
dried (MgSO4), filtered, concentrated, and purified by column chromatography (1:8→1:6 
EtOAc-cyclohexane). Yield 92% (1.50 g, 1.11 mmol). Rf = 0.74 (1:5 EtOAc-cyclohexane); []D 
= +70.3 (c 1.0, DCM); IR: max = 2923, 2855 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ = 7.53-7.23 
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(m, 30 H, Ph), 5.34 (d, 2 H, J1,2 = 3.7 Hz, H-1), 4.03 (bd, 2 H, J4,5 = 9.3 Hz,  H-5), 3.80 (m, 2 H, 
OCH2), 3.78-3.41 (m, 8 H, OCH2), 3.57 (t, 2 H, J2,3= J3,4=9.3 Hz, H-3), 3.51-3.41 (m, 4 H, H-4, 
H-6a), 3.39 (dd, 2 H, H-2), 3.24 (m, 2 H, OCH2), 3.13 (dd, 2 H, J6a,6b = 10.0 Hz, J5,6b = 3.3 Hz, 
H-6b), 1.65-1.56 (m, 12 H, CH2), 1.38-1.04.89 (m, 36 H, CH2), 0.93-0.82 (m, 18 H, CH3); 
13
C 
NMR (75.5 MHz, CDCl3): δ = 144.0, 128.8, 127.6, 126.8 (Ph), 93.6 (C-1), 86.1 (Ph3C), 81.5 (C-
3), 80.6 (C-2), 78.1 (C-4), 73.7, 73.0, 71.3 (OCH2), 70.0 (C-5), 62.0 (C-6), 31.8-22.5 (CH2), 14.1 
(CH3); ESI MS: m/z = 1353.8 [M + Na]
+
. Anal. Calcd for C86H122O11: C, 77.55; H, 9.23. Found: 
C, 77.67; H, 9.31. 
2,3,4,2’,3’,4-Hexa-O-tetradecyl-6,6’-di-O-trityl-’-trehalose (34). To a solution of 32 (1.00 
g, 1.21 mmol) in dry DMF (11 mL), NaH (0.87 g, 21.78 mmol) was added and the mixture was 
stirred at 0 ºC for 10 min. 1-Bromotetradecane (6.68 mL, 21.78 mmol) was added dropwise, 
under Ar atmosphere, and the mixture was stirred overnight at 60 ºC. The reaction was quenched 
with MeOH (5 mL) and stirred for 10 min. Solvents were removed and the resulting residue was 
suspended in DCM (50 mL). The suspension was washed with H2O (3 x 15 mL) and the organic 
layer was dried (MgSO4), filtered, concentrated and purified by column chromatography (1:50 
→ 1:30 EtOAc-cyclohexane). Yield 77% (1.50 g, 0.93 mmol). Rf = 0.77 (1:15 EtOAc-
cyclohexane); []D = +50.2 (c 1.0, DCM); 
1
H NMR (300 MHz, CDCl3): δ = 7.52-7.22 (m, 30 H, 
Ph), 5.33 (d, 2 H, J1,2 = 3.6 Hz, H-1), 4.03 (bd, 2 H, J4,5 = 9.4 Hz,  H-5), 3.79 (m, 2 H, OCH2), 
3.71-3.52 (m, 8 H, OCH2), 3.55(t, 2 H, J2,3 = J3,4 = 9.4 Hz, H-3),3.44 (t, 2 H, H-4), 3.46-3.35 (m, 
6 H, OCH2, H-6a, H-2), 3.22 (m, 2 H, OCH2), 3.12 (dd, 2 H, J6a,6b = 10.0 Hz, J5,6b = 3.1 Hz, H-
6b), 1.76-156 (m, 12 H, CH2), 1.28 (m, 132 H, CH2), 0.91 (t, 18 H, 
3
JH,H = 6.3 Hz, CH3); 
13
C 
NMR (75.5 MHz, CDCl3): δ = 144.1, 128.8, 127.6, 126.8 (Ph), 93.7 (C-1), 86.2 (Ph3C), 81.4 (C-
3), 80.6 (C-2), 78.2 (C-4), 73.7, 73.0, 71.3 (OCH2), 70.5(C-5), 62.1 (C-6), 31.9- 22.7 (CH2), 14.1 
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(CH3); ESI MS: m/z = 2027.4 [M + Na]
+
. Anal. Calcd for C134H218O11: C, 80.26; H, 10.96. 
Found: C, 80.35; H, 11.05. 
2,3,4,2’,3’,4-Hexa-O-hexyl-’-trehalose (35). To a solution of 33 (0.68 g, 0.52 mmol) in 1:1 
DCM-MeOH (25 mL), p-toluenesulphonic acid monohydrate (0.08 g, 0.42 mmol) was added and 
the solution was stirred at rt for 4 h. The mixture was diluted with DCM, washed with saturated 
aqueous NaHCO3, dried (MgSO4), filtered and concentrated. The resulting residue was purified 
by column chromatography (1:8→1:2 EtOAc-cyclohexane). Yield 48% (0.21 g, 0.24 mmol); Rf 
= 0.25 (1:2 EtOAc-cyclohexane); []D = +103.0 (c 1.0, DCM); 
1
H NMR (300 MHz, CDCl3): δ = 
5.06 (d, 2 H, J1,2 = 3.7 Hz, H-1), 3.90 (dt, 2 H, J4,5 = 9.2 Hz, J5,6a = J5,6b = 2.9 Hz, H-5), 3.79 (m, 
4 H, OCH2), 3.73-3.63 (m, 8 H, H-6a, H-6b, OCH2), 3.60-3.43 (m, 4 H, OCH2), 3.57 (t, 2 H, 
J2,3= J3,4= 9.2 Hz, H-3), 3.23 (t, 1 H, H-4), 3.18 (dd, 1 H, H-2), 2.03 (bs, 2 H, OH), 1.60-1.47 (m, 
12 H, CH2), 1.37-1.27 (m, 36 H, CH2), 0.87 (m, 18 H, CH3); 
13
C NMR (75.5 MHz, CDCl3): δ = 
93.6 (C-1), 81.0 (C-3), 80.4 (C-2), 77.9 (C-4), 73.6, 73.3, 71.5 (OCH2), 71.4 (C-5), 61.8 (C-6), 
31.8- 22.6 (CH2), 14.0 (CH3); ESI MS: m/z = 869.7 [M + Na]
+
, 885.7 [M + K]
+
. Anal. Calcd for 
C48H94O11: C, 68.05; H, 11.18. Found: C, 67.89; H, 11.04. 
2,3,4,2’,3’,4-Hexa-O-tetradecyl-’-trehalose (36). To a solution of 34 (1.49 g, 0.74 mmol) in 
1:1 DCM-MeOH (36 mL), p-toluenesulphonic acid monohydrate (0.11 g, 0.50 mmol) was added 
and the solution was stirred at rt for 4 h. The mixture was diluted with DCM, washed with 
saturated aqueous NaHCO3, dried (MgSO4), filtered and concentrated. Purification by column 
chromatography (1:9→1:5 EtOAc-cyclohexane) of the residue afforded 37. Yield 47% (0.53 g, 
0.34 mmol); Rf = 0.20 (1:5 EtOAc-cyclohexane); []D = +58.4 (c 1.0, DCM); 
1
H NMR (300 
MHz, CDCl3): δ = 5.06 (d, 2 H, J1,2 = 3.7 Hz, H-1), 3.90 (dt, 2 H, J4,5 = 9.2 Hz, J5,6a = J5,6b = 2.6 
Hz, H-5), 3.84-3.64 (m, 4 H, OCH2), 3.73-3.63 (m, 12 H, H-6a, H-6b, OCH2), 3.58 (t, 2 H, J2,3= 
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J3,4= 9.2 Hz, H-3), 3.24 (t, 2 H, H-4), 3.19 (dd, 2 H, H-2), 1.86 (bs, 2 H, OH), 1.61-1.49 (m, 12 
H, CH2), 1.26 (bs, 132 H, CH2), 0.88 (t, 18 H, 
3
JH,H = 6.9 Hz,CH3); 
13
C NMR (75.5 MHz, 
CDCl3): δ = 93.7 (C-1), 81.1 (C-3), 80.5 (C-2), 78.0 (C-4), 73.6, 73.3, 71.6 (OCH2), 71.1 (C-5), 
61.9 (C-6), 31.9- 22.7 (CH2), 14.1 (CH3); ESI MS: m/z = 1543.2 [M + Na]
+
. Anal. Calcd for 
C96H190O11: C, 75.83; H, 12.59. Found: C, 75.70; H, 12.41. 
6,6’-Dideoxy-2,3,4,2’,3’,4-hexa-O-hexyl-6,6’-diiodo-’-trehalose (37). To a solution of 35 
(0.10 g, 0.12 mmol) in toluene (5 mL), triphenylphosphine (0.11 g, 0.43 mmol) and imidazole 
(0.05 g, 0.81 mmol) were added and the mixture was stirred at rt until complete dissolution. 
Iodine (0.11 g, 0.40 mmol) was added in portions and the solution was vigorously stirred at 70 
ºC for 5 h. Satd. aqueous NaHCO3 solution (10 mL) was added and the mixture was stirred for 5 
min. Additional iodine was then added until the aqueous solution turned to a slightly brown 
color, then aqueous 10% Na2S2O3 was added until complete decoloration of both organic and 
aqueous layer. The organic layer was then separated, dried (MgSO4), filtered, concentrated and 
purified by column chromatography (1:15 EtOAc-cyclohexane). Yield 94% (0.12 g, 0.12 mmol); 
Rf = 0.75 (1:8 EtOAc-cyclohexane); []D = +50.1 (c 1.0, DCM); 
1
H NMR (300 MHz, CDCl3): δ 
= 5.17 (d, 2 H, J1,2 = 3.3 Hz, H-1), 3.83 (m, 4 H, OCH2), 3.72-3.47 (m, 12 H, H-5, H-3, OCH2), 
3.39 (m, 4 H, H-6a, H-6b), 3.24 (dd, 1 H, Hz, J2,3 = 9.1 Hz, H-2), 3.05 (t, 1 H, J3,4= J3,4= 9.1 Hz, 
H-4), 1.62-1.49 (m, 12 H, CH2), 1.30 (m, 36 H, CH2), 0.89 (m, 18 H, CH3); 
13
C NMR (75.5 
MHz, CDCl3): δ = 92.9 (C-1), 81.9 (C-4), 80.8 (C-3), 80.2 (C-2), 73.5, 73.4, 71.9 (OCH2), 69.1 
(C-5), 31.8- 22.6 (CH2), 14.0 (CH3), 8.7 (C-6); ESI MS: m/z = 1089.6 [M + Na]
+
. Anal. Calcd for 
C48H92I2O9: C, 54.03; H, 8.69. Found: C, 53.88; H, 8.77. 
6,6’-Dideoxy-2,3,4,2’,3’,4-hexa-O-tetradecyl-6,6’-diiodo-’-trehalose (38). To a solution of 
36 (0.44 g, 0.29 mmol) in toluene (13 mL), triphenylphosphine (0.27 g, 1.02 mmol) and 
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imidazole (0.07 g, 1.89 mmol) were added and the mixture was stirred at rt until complete 
dissolution. Iodine (0.26 g, 0.93 mmol) was added in portions and the solution was vigorously 
stirred at 70 ºC for 5 h. Satd. NaHCO3 solution (20 mL) was added and the mixture was stirred 
for 5 min. Additional iodine was then added until the aqueous solution got slightly brown, and 
then an aqueous 10% Na2S2O3 solution was added until complete decoloration of both organic 
and aqueous layer. The organic layer was then separated, dried (MgSO4), filtered, concentrated, 
and purified by column chromatography (1:25 EtOAc-cyclohexane). Yield 96% (0.52 g, 0.28 
mmol); Rf = 0.69 (1:20 EtOAc-cyclohexane); []D = +47.2 (c 1.0, DCM);,
1
H NMR (300 MHz, 
CDCl3): δ = 5.17 (d, 2 H, J1,2 = 3.5 Hz, H-1), 3.83 (m, 4 H, OCH2), 3.70-3.48 (m, 12 H, H-5, H-
3, OCH2), 3.42 (dd, 2 H, J6a,6b = 10.7 Hz, J5,6a = 2.9 Hz, H-6a), 3.36 (dd, 2 H, J5,6a = 5.2 Hz, H-
6b), 3.24 (dd, 1 H, Hz, J2,3 = 9.4 Hz, H-2), 3.05 (t, 1 H, J3,4= J3,4= 9.4 Hz, H-4), 1.59-1.51 (m, 12 
H, CH2), 1.26 (bs, 132 H, CH2), 0.88 (t, 18 H, 
3
JH,H = 6.9 Hz, CH3); 
13
C NMR (75.5 MHz, 
CDCl3): δ = 92.9 (C-1), 81.9 (C-4), 80.8 (C-3), 80.3 (C-2), 73.6, 73.5, 71.9 (OCH2), 69.1 (C-5), 
31.9- 22.7 (CH2), 14.1 (CH3), 8.7 (C-6); ESI MS: m/z = 1763.0 [M + Na]
+
. Anal. Calcd for 
C96H188I2O9: C, 66.25; H, 10.89. Found: C, 66.09; H, 10.74. 
6,6’-Di-(2-tert-butoxycarbonylaminoethylthio)-2,3,4,2’,3’,4’-hexa-O-hexyl-’-trehalose 
(39). To a solution of 37 (0.11 g, 0.10 mmol) in dry DMF (12 mL), Cs2CO3 (0.09 g, 0.29 mmol) 
and tert-butyl N-(2-mercaptoethyl)carbamate (49L, 0.29 mmol) were added, under Ar 
atmosphere, and the reaction mixture was stirred at 60 ºC for 24 h. The reaction mixture was 
concentrated and the crude product was dissolved in DCM (20 mL) and washed with H2O (2 x 
30  mL). The organic phase was dried (MgSO4), filtered, concentrated and purified by column 
chromatography (1:8 → 1:6 EtOAc-cyclohexane). Yield 85 %(0.10 g, 0.08 mmol). Rf = 0.26 (1:5 
EtOAc-cyclohexane); []D = +86.4 (c 1.0, DCM); IR: max = 3350, 2928, 2855, 1710 cm
-1
,
1
H 
 47 
NMR (300 MHz, CDCl3): δ = 5.12 (d, 2 H, J1,2 = 3.3 Hz, H-1), 4.99 (bs, 2 H, NHBoc), 4.01 
(ddd, 2 H, J4,5= 9.2 Hz, J5,6b = 6.3 Hz,  J5,6a = 2.7 Hz, H-5), 3.81 (m, 6 H, H-3, OCH2), 3.70-3.46 
(m, 8 H, OCH2), 3.58 (t, 2 H, J2,3= J3,4= 9.2 Hz, H-3), 3.29 (q, 2 H, 
3
JH,H = 
3
JH,NH = 6.0 Hz, 
CH2N), 3.23 (dd, 1 H, H-2), 3.16 (t, 1 H, H-4), 2.82 (dd, 1 H, J6a,6b = 13.5 Hz,  H-6a), 2.72 (dd, 1 
H, H-6b), 2.69 (t, 2 H, CH2S), 1.60-1.47 (m, 12 H, CH2), 1.43 (s, 18 H, C(CH3)3), 1.34-1.28 (m, 
36 H, CH2), 0.89 (m, 18 H, CH3); 
13
C NMR (75.5 MHz, CDCl3): δ = 155.7 (CO), 92.3 (C-1), 
81.0 (C-3), 80.5 (C-2), 80.4 (C-4), 79.2 (CMe3), 73.4, 73.2, 71.7 (OCH2), 71.2 (C-5), 39.8 
(CH2S), 33.8 (C-6), 33.7 (CH2N), 31.8- 30.2 (CH2), 28.4 (CMe3), 25.9, 25.8, 22.6 (CH2), 14.0 
(CH3); ESI MS: m/z = 1187.9 [M + Na]
+
, 1203.8 [M + K]
+
. Anal. Calcd for C62H120N2O13S2: C, 
63.88; H, 10.38; N, 2.40 Found: C, 63.69; H, 10.21; N, 5.19. 
6,6’-Di-(2-tert-butoxycarbonylaminoethylthio)-2,3,4,2’,3’,4’-hexa-O-tetradecyl-’-
trehalose (40). To a solution of 38 (0.28 g, 0.13 mmol) in dry DMF (15 mL), Cs2CO3 (0.12 g, 
0.36 mmol) and tert-butyl N-(2-mercaptoethyl)carbamate (61L, 0.36 mmol) were added, under 
Ar atmosphere, and the reaction mixture was stirred at 60 ºC for 24 h. The solvent was 
evaporated and the crude product was dissolved in DCM (20 mL) and washed with H2O (2 x 30 
mL). The organic phase was separated, dried (MgSO4), filtered, concentrated and purified by 
column chromatography (1:8 EtOAc-cyclohexane). Yield 99% (0.24 g, 0.13 mmol). Rf = 0.53 
(1:5 EtOAc-cyclohexane); []D = +49.3 (c 1.0, DCM); 
1
H NMR (300 MHz, CDCl3): δ = 5.12 (d, 
2 H, J1,2 = 3.4 Hz, H-1), 4.99 (bs, 2 H, NHBoc), 4.01 (ddd, 2 H, J4,5= 9.6 Hz, J5,6a = 2.6 Hz, J5,6b 
= 6.1 Hz, H-5), 3.81 (m, 4 H, OCH2), 3.69-3.46 (m, 8 H, OCH2), 3.58 (t, 2 H, J2,3= J3,4= 9.6 Hz, 
H-3), 3.30 (bq, 2 H, 
3
JH,H = 
3
JH,NH = 6.0 Hz, CH2N), 3.23 (dd, 1 H, H-2), 3.17 (t, 1 H, H-4), 2.83 
(dd, 1 H, J6a,6b = 13.7 Hz, H-6a), 2.72 (dd, 1 H, H-6b), 2.69 (t, 2 H, CH2S), 1.60-1.51 (m, 12 H, 
CH2), 1.44 (s, 18 H, CMe3), 1.26 (bs, 132 H, CH2), 0.88 (t, 18 H, 
3
JH,H = 6.9 Hz, CH3); 
13
C NMR 
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(75.5 MHz, CDCl3): δ = 155.7 (CO), 92.3 (C-1), 81.0 (C-3), 80.5 (C-2), 80.4 (C-4), 79.3 (CMe3), 
73.5, 73.2, 71.6 (OCH2), 71.2 (C-5), 39.8 (CH2S), 33.8 (C-6), 33.7 (CH2N), 31.9, 30.7, 30.5, 
30.3, (CH2), 29.7 (CMe3), 29.4-22.7 (CH2), 14.1 (CH3); ESI MS: m/z = 1861.5 [M + Na]
+
. Anal. 
Calcd for C110H216N2O13S2: C, 71.84; H, 11.84; N, 1.52; S, 3.49. Found: C, 71.90; H, 11.72; N, 
1.44; S, 3.38. 
6,6’-Di-(2-aminoethylthio)-2,3,4,2’,3’,4’-hexa-O-hexyl-’-trehalose Dihydrochloride (7). 
Treatment of 39 (0.10 g, 0.09 mmol) with 1:1 TFA-DCM (2 mL) and freeze-drying from 10:1 
H2O/0.1 N HCl solution afforded 7. Yield quant. (0.09 g, 0.09 mmol); Rf  = 0.72 (10:1:1CH3CN-
H2O-NH4OH); []D = +90.3 (c 1.0, DCM); IR: max = 3300, 2928, 2859, 1099 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3): δ =  8.13 (bs, 6 H, NH3
+
), 5.20 (d, 2 H, J1,2 = 3.2 Hz, H-1), 3.98 (dt, 2 H, J4,5 
= 9.5 Hz, J5,6a = J5,6b = 4.3 Hz, H-5), 3.79 (m, 4 H, OCH2), 3.69-3.43 (m, 8 H, OCH2), 3.56 (t, 2 
H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.25 (dd, 2 H, H-2), 3.18 (bs, 4 H, CH2N), 3.11 (t, 2H, H-4), 2.97 
(bd, 2 H, J6a,6b = 14.0 Hz, H-6a), 2.82 (m, 6 H, CH2S, H-6b), 1.59-1.50 (m, 12 H, CH2), 1.28 (m, 
36 H, CH2), 0.88 (m, 18 H, CH3); 
13
C NMR (75.5 MHz, CDCl3): δ = 91.9 (C-1), 80.9 (C-3), 80.2 
(C-2), 80.0 (C-4), 73.5, 73.4, 71.8 (OCH2), 71.0 (C-5), 39.4 (CH2N), 34.4 (C-6), 31.8(CH2S), 
31.7,30.6, 30.4, 30.2, 25.9, 25.8, 22.6, 22.5 (CH2), 14.0 (CH3); ESI MS: m/z = 965.9 [M – 2Cl]
+
. 
Anal. Calcd for C52H102N2O9S2·2HCl: C, 60.14; H, 10.29; N, 2.70; S, 6.17. Found: C, 59.86  H, 
10.02; N, 2.41; S, 5.88. 
6,6’-Di-(2-aminoethylthio)-2,3,4,2’,3’,4’-hexa-O-tetradecyl-’-trehalose Dihydrochloride 
(8). Treatment of 40 (0.09 mg, 0.05 mmol) with 1:1 TFA-DCM (1 mL) and freeze-drying from 
10:1 H2O/0.1 N HCl solution afforded 8. Yield quant (0.09 g, 0.05 mmol); Rf = 0.21 (EtOAc); 
[]D = +61.2 (c 1.0, DCM); 
1
H NMR (300 MHz, CDCl3): δ =  6.39 (bs, 6 H, NH3
+
), 5.21 (d, 2 H, 
J1,2 = 3.5 Hz, H-1), 3.97 (dt, 2 H, J4,5 = 9.6 Hz, J5,6a = J5,6b = 4.7 Hz, H-5), 3.79 (m, 4 H, OCH2), 
 49 
3.69-3.43 (m, 8 H, OCH2), 3.56 (t, 2 H, J2,3 = J3,4 = 9.6 Hz, H-3), 3.25 (dd, 2 H,  H-2), 3.18 (t, 4 
H, 
3
JH,H = 6.3 Hz,CH2N), 3.11 (t, 2H, H-4), 3.07-2.94 (m, 4 H, H-6a, H-6b), 2.82 (m, 4 H, 
CH2S), 1.58-1.49 (m, 12 H, CH2), 1.26 (bs, 132 H, CH2), 0.88 (m, 18 H,
 3
JH,H = 7.0 Hz, CH3); 
13
C NMR (75.5 MHz, CDCl3): δ = 91.9 (C-1), 80.9 (C-3), 80.2 (C-2), 80.0 (C-4), 73.5, 73.4, 71.8 
(OCH2), 71.0 (C-5), 39.5 (CH2N), 34.6 (C-6), 31.9(CH2S), 31.9-22.7 (CH2), 14.1 (CH3); ESI 
MS: m/z=1639.4 [M – 2 Cl]+. Anal. Calcd for C100H200N2O9S2·2HCl: C, 70.17; H, 11.90; N, 
1.64; S, 3.75 Found: C, 69.82; H, 11.77; N, 1.39; S, 3.41. 
6,6’-Dideoxy-2,3,4,2’,3’,4’-hexa-O-hexanoyl-6,6’-diiodo-’-trehalose (42). To a solution of 
6,6’-dideoxy-6,6’-diiodo-trehalose41, (5.78 g, 10.30 mmol) and DMAP (6.37 g, 52.20 mmol) in 
dry DMF (80 mL), hexanoic anhydride (16 mL, 69.60 mmol) was added dropwise, under Ar 
atmosphere at 0º C and the reaction mixture was stirred at rt for 6 h. Then MeOH (60 mL) was 
added and the mixture was stirred ad rt for 2 h. The solution  was poured into H2O-ice mixture 
(100 mL) and extracted with DCM (50 mL). The organic phase was then washed with 2N H2SO4 
(2 x 50 mL), H2O (2 x 50 mL) and saturated aqueous NaHCO3 (2 x 50 mL), dried (MgSO4), 
filtered, concentrated and purified by column chromatography (1:12 EtOAc-petroleum ether). 
Yield 76% (1.20 g, 7.82 mmol)Rf = 0.35 (1:6 EtOAc-petroleum ether); 
1
H NMR (300 MHz, 
CDCl3): δ = 5.44 (t, 1 H, J2,3 = J3,4 = 9.5 Hz, H-3), 5.35 (d, 1 H, J1,2 = 3.7 Hz, H-1), 5.1 (dd, 1 H, 
H-2), 4.84  (t, 1 H, J4,5  = 9.5 Hz,  H-4), 3.82 (ddd, 1 H, J5,6a = 2.5 Hz, H-5), 3.11 (dd, 1 H, J6a,6b = 
11.0 Hz,  H-6a), 2.97 (dd, 1 H, H-6b), 2.22 (m, 6 H, H-2Hex), 1.58 (m, 6 H, H-3Hex), 1.17 (m, 12 
H, H-4Hex, H-5Hex), 0.84 (m, H-6Hex).
13
C NMR (75.5 MHz, CDCl3): δ = 172.6, 172.5, 172.4 
(CO), 91.5 (C-1), 72.0 (C-4), 70.0 (C-5), 69.3 (C-3), 69.2 (C-2), 34 (C-2Hex), 31.2 (C-4Hex), 24.4 
(C-3Hex), 22.2 (C-5Hex), 14.1 (C-6Hex), 2.6 (C-6Hex). ESI MS: m/z = 1173.4 [M + Na]
+
. Anal. 
Calcd for C47H78I2O15: calcd. C, 49.65; H, 6.92; found: C, 50.12; H, 7.01.  
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2,3,4,2’,3’,4’-Hexa-O-hexanoyl-6,6’-bis(2-tert-butoxycarbonylaminoethylthio)-,’-
trehalose (43). To a solution of 42 (0.19 g, 0.17 mmol) in dry DMF (1.5 mL), Cs2CO3 (0.15 g, 
0.47 mmol) and tert-butyl N-(2-mercaptoethyl)carbamate (80 L, 0.47 mmol) were added, under 
Ar atmosphere, and the reaction mixture was stirred at 60º C for 24 h. The reaction mixture was 
concentrated and the crude product was dissolved in DCM (10 mL) and washed with water (2 x 
20  mL). The organic phase was dried (MgSO4), filtered and concentrated. The residue was 
purified by column chromatography (1:3 EtOAc-cyclohexane). Yield 58% (0.12 mg, 0.10 
mmol). Rf = 0.52 (1:2 EtOAc-cyclohexane); []D = +84.5 (c 1.0, DCM); IR: max = 2959, 1749, 
1709 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ = 5.43 (t, 1 H, J3,2 = J3,4= 9.5 Hz, H-3), 5.25 (d, 1 H, 
J1,2= 4.1 Hz, H-1), 5.00 (dd, 1 H, H-2), 4.94 (t, 1 H, H-4), 3.88 (m, 1 H, H-5), 3.2 (s, 2 H, 
CH2N), 2.61 (m, 2 H, CH2S), 2.52 (m, 2 H, H-6ª, H-6b), 2.23 (m, 6 H, H-2Hex), 1.50 (m, 6 H, H-
3Hex),1.41 (s, 9 H, CMe3), 1.23 (m, 12 H, H-4Hex, H-5Hex), 0.83 (t, 9 H,
 
H-6Hex); 
13
C NMR (75.5 
MHz, CDCl3): δ = 172.6, 172.5, 172.4 (C-1Hex), 155.7 (CO carbamate), 91.4 (C-1), 71.2 (C-4), 
71.1 (C-5), 69.6 (C-2, C-3), 39.7 (CH2N), 34.1, 34.0 (C-2Hex), 33.8 (CH2S), 24.4 (C-3Hex), 28.4 
(CMe3), 22.3 (C-4Hex, C-5Hex), 13.8 (C-6Hex); ESI MS: m/z=1271.8 [M + Na]
+
. Anal. Calcd for 
C62H108N2O19S2: C, 59.59; H, 8.71; N, 2.24; S, 5.13; found: C, 59.67; H, 8.69; N, 2.32; S, 4.89. 
2,3,4,2’,3’,4’-Hexa-O-hexanoyl-6,6’-bis(2-tert-aminoethylthio)-,’-trehalose 
dihydrochloride (9). Treatment of 43 (0.07 g, 0.04 mmol) with 1:1 TFA-DCM (2 mL) and 
freeze-drying from 10:1 H2O/0.1 N HCl solution afforded 9. Yield quant (0.07 g, 0.04 mmol). 
[]D = + 66.7 (c 0.9, EtOAc) ; IR: max = 2957, 1740, 1686 cm
-1
.
 1
H NMR (300 MHz, DMSO-
d6): δ = 5.35 (t, J2,3 = 9.7 Hz, 1 H, H-3), 5.29 (d, 1 H, J1,2 = 4.0 Hz, H-1), 5.08 (m, 2 H, H-2, H-
3), 3.95 (m, 1 H, H-5), 2.95 (bs, 2 H, CH2N), 2.69 (t, 2 H, JH,H = 7.0 Hz, CH2S), 2.67 (bd, 2 H, 
H-6ª, H-6b), 2.27 (m, 6 H, H-2Hex), 1.49 (m, 6 H, H-3Hex), 1.24 (m, 12 H, H-4Hex, H-5Hex), 0.85 (t, 
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9 H,
 
H-6Hex); 
13
C NMR (75.5 MHz, DMSO-d6): δ = 171.8, 171.7 (CO), 90.9 (C-1), 70.9 (C-5), 
70.0, 69.2, (C-2, C-4), 69.4 (C-3), 39.2 (CH2N), 31.5 (C-6), 33.9 (C-2Hex), 30.3 (CH2S), 23.9 (C-
3Hex), 30.6 (C-4Hex), 21.8 (C-5Hex), 13.3 (C-6Hex); ESI MS: m/z = 1049.6 [M]
+
. Anal. Calcd for 
C52H94Cl2N2O15S2: C, 55.65; H, 8.44; N, 2.50; S, 5.71; found: C, 55.29; H, 8.18; N, 2.14; S, 5.33 
6,6’-Diazido-6,6’-dideoxy-2,3,4,2’,3’,4’-hexa-O-hexanoyl-,’-trehalose (45). To a solution 
of 42 (1.58 g, 1.37 mmol) in dry DMF (8 mL), NaN3 (0.25 g, 3.60 mmol) was added. The 
reaction mixture was stirred overnight at 40 ºC, under Ar atmosphere. The mixture was poured 
into H2O-ice mixture (20 mL), and the product was extracted with DCM (4 x 20 mL). The 
organic phase was dried (MgSO4), filtered and concentrated. The residue was purified by column 
chromatography (1:12 EtOAc-cyclohexane) to afford 45. Yield 72% (0.91 g, 0.98 mmol). Rf = 
0.53 (1:6 EtOAc-cyclohexane). []D = +108.7 (c 1.0, DCM); IR: max = 2958, 2104, 1750, 735 
cm
-1
; 
1
H NMR (300 MHz, CD3OD): δ = 5.52 (t, 2 H, J2,3 =  J3,4 = 9.8 Hz, H-3), 5.41 (d, 2 H, J1,2 
= 4.0 Hz, H-1), 5.13 (dd, 2 H,
 
H-2), 5.09 (t,  2 H, J4,5 =  9.8 Hz,  H-4), 4.08 (ddd, 2 H, J5,6a = 7.0 
Hz, J5,6b = 2.6 Hz, H-5), 3.44 (dd, 2 H, J6a,6b = 13.0 Hz, H-6ª), 2.97 (dd, 2 H, H-6b), 2.33 (m, 12 
H, H-2Hex), 1.58 (m, 12 H, H-3Hex), 1.33 (m, 24 H, H-4Hex,H-5Hex), 0.91 (m, 18 H, H-6Hex); 
13
C 
NMR (75.5 MHz, CD3OD): δ = 175.2-174.2 (CO), 93.7 (C-1), 71.5 (C-3), 71.3 (C-2), 71.6 (C-
5), 71 (C-4), 52.2 (C-6), 34.9 (C-2Hex), 33.2 (C-4Hex), 25.8 (C-3Hex), 23.6 (C-5Hex), 14.8 (C-6Hex); 
ESI MS: m/z = 1003.5 [M + Na]
+
.  Anal. Calcd for C25H43N8O15: calcd. C, 58.76; H, 8.22; N, 
8.57; found: C, 58.84; H, 8.32; N, 8.60. 
6,6’-Di-(4-tert-butoxycarbonylaminomethyl-1H-1,2,3-triazol-1-yl)-6,6’-dideoxy-
2,3,4,2’,3’,4’-hexa-O-hexanoyl-,’-trehalose (46). To a solution of 44 (0.25 g, 0.25 mmol) 
and 45 (0.08 g, 0.56 mmol) in H2O-
t
BuOH 9:1 (15 mL) the Cu-supported catalyst Si-BPA·Cu
+ 
(0.02 g) was added and the reaction mixture was refluxed for 36 h at 85 ºC. The catalyst was 
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filtered and the solvent was concentrated. The residue was purified by column chromatography 
(1:1→2:1 EtOAc-cyclohexane). Yield quant. (0.33 g, 0.25 mmol). Rf=0.73 (2:1 EtOAc-
cyclohexane). []D = +56.7 (c 1.0, DCM); IR: max = 2957, 1752, 1714, 735 cm
-1
; 
1
H NMR (300 
MHz, CDCl3): δ = 7.52 (s, 2 H, =CH), 5.45 (t, 2 H, J2,3 = J3,4 = 9.8 Hz , H-3), 5.30 (bs, 2 H, 
NHBoc), 4.97 (dd, 2 H,
  
J1,2= 4.0 Hz, H-2), 4.87 (t, 2 H, J4,5 = 9.8 Hz, H-4), 4.83 (d, 2 H, H-1), 
4.48 (bd, 2 H, J6a,6b = 13.7 Hz, H-6a), 4.37 (d, 4 H, JH,H = 6.0 Hz, CH2 triazole), 4.12 (dd, 2 H, 
J5,6b = 8.8 Hz, H-6b), 4.07 (m, 2 H, H-5), 2.25 (m, 12 H, H-2Hex), 1.55 (m, 12 H, H-3Hex), 1.46 (s, 
18 H, CMe3), 1.29 (m, 24 H, H-4Hex, H-5Hex), 0.89 (m, 18 H, H-6Hex); 
13
C NMR (75.5 MHz, 
CD3OD): δ = 173.5-173.2 (CO ester), 155.5 (CO carbamate), 146.0 (C-4 triazole), 122.3 (C-5 
triazole), 91.7 (C-1), 79.5 (CMe3), 69.9 (C-3, C-5), 69.8 (C-4), 69.3 (C-2), 50.7 (C-6), 36.4 
(CH2-triazole), 34.3 (C-2Hex), 31.9 (C-4Hex), 28.7 (CMe3) 24.6 (C-3Hex), 22.6 (C-5Hex), 14.1 (C-
6Hex); ESI MS: m/z = 1313.4 [M + Na]
+
. Anal. Calcd for C64H106N8O19: calcd. C, 59.52; H, 8.27; 
N, 8.68; found: C, 59.61; H, 8.33; N, 8.84. 
6,6’-Di-(4-Aminomethyl-1H-1,2,3-triazol-1-yl)-6,6’-dideoxy-2,3,4,2’,3’,4’-hexa-O-hexanoyl) 
-,’-trehalose Dihydrochloride (47). Treatment of 46 (0.30 g, 0.23 mmol) with 1:1 TFA-
DCM (4 mL) and freeze-drying from 10:1 H2O/0.1 N HCl solution afforded 47. Yield 97% (0.26 
g, 0.22 mmol). []D = +48.9 (c 1.0, MeOH); IR: max = 2956, 1751, 1464, 1026 cm
-1
; 
1
H NMR 
(300 MHz, CD3OD): δ = 8.05 (s, 2 H, CH triazole), 5.49 (t, 2 H, J3,4 = J2,3 = 9.8 Hz, H-3), 5.06 
(dd, 2 H,
 
J1,2 = 4.0 Hz, H-2), 4.96 (d, 2 H, J1,2 = 3.6 Hz, H-1), 4.95 (t, 2 H, J4,5 = 9.8 Hz, H-4), 
4.63 (dd, 2 H, J5,6a = 2.6 Hz, J5,6b = 14.6 Hz, H-6), 4.53 (dd, 2 H, J5,6b = 7.9 Hz, H-6b), 4.27 (bs, 
4 H, CH2NH2), 4.24 (m, 1 H, H-5), 2.32 (m, 12 H, H-2Hex), 1.59 (m, 12 H, H-3Hex), 1.33 (m, 24 
H, H-4Hex,H-5Hex), 0.93 (m, 18 H, H-6Hex); 
13
C NMR (75.5 MHz, CD3OD): δ = 174.5-173.6 
(CO), 141.5 (C-4 triazole) 127.1 (C-5 triazole), 92.7 (C-1), 71.2 (C-2), 70.6 (C-3), 70.4 (C-4), 
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70.3 (C-5), 51.5 (C-6), 35.2 (CH2NH2), 34.8 (C-2Hex), 32.1 (C-4Hex), 25.8 (C-3Hex), 22.6 (C-5Hex), 
14.2 (C-6Hex); ESI MS: m/z = 1091.4 [M]
+
. Anal. Calcd for C54H92N8O15: calcd. C, 55.71; H, 
7.96; N, 9.62; found: C, 55.48; H, 7.77; N, 9.97. 
6,6’-Di-[4-(2-N’-(2-(N-tert-butoxycarbonyl)aminoethyl)thioureido))methyl-1H-1,2,3-
triazolyl-]2,3,4,2’,3’,4’-hexa-O-hexanoyl)-6,6’-dideoxy-,’-trehalose (48). To a solution of 
47 (0.14 g, 0.12 mmol) and Et3N (37 L, 0.36 mmol) in DCM (10 mL), tert-butyl N-(2-
isothiocyanoethyl) carbamate (0.07 g, 0.36 mmol) was added and the reaction mixture was 
stirred overnight at rt. The reaction mixture was washed with aqueous diluted HCl (3 x 10 mL) 
and the organic phase was dried (MgSO4), filtered, and concentrated. The residue was purified 
by column chromatography (2:1 → 3:1 EtOAc-cyclohexane). Yield 67% (0.12 g, 0.08 mmol). Rf 
= 0.40 (3:1 EtOAc-cyclohexane). []D = +59.8 (c 1.0, DCM); UV (DCM): 249 nm (mM 53.9); 
IR: max = 2959, 1752, 1701, cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ = 7.80 (s, 2 H, CH triazole), 
7.07 (bs, 4 H, NHCS), 5.39 (t, 2 H, J3,4 = J2,3 = 9.7 Hz , H-3), 5.29 (bs,  2 H, NHBoc), 4.98-4.76 
(m, 4 H, H-1, H-4, CH2 triazole), 4.62 (dd, 2 H, H-2), 4.47 (d, 2 H, J6a,6b = 14.0 Hz, H-6ª), 4.28 
(dd, 2 H, J5,6b = 8.0 Hz, H-6b), 3.97 (bt, 2 H, H-5), 3.60 (bs, 4 H, CH2CH2NHBoc), 3.31 (m, 4 H, 
3
JH,H = 5.4 Hz, CH2NHBoc), 2.22 (m, 12 H, H-2Hex), 1.53 (m, 12 H, H-3Hex), 1.39 (s, 18 H, 
CMe3), 1.27 (m, 24 H, H-4Hex, H-5Hex), 0.86 (m, 18 H, H-6Hex); 
13
C NMR (75.5 MHz, CDCl3): δ 
= 173.2-172.5 (CO ester), 156.2 (CO carbamate), 141.5 (C-4 triazole),  124.3 (C-5 triazole), 96.7 
(C-1), 79.7 (CMe3), 69.6-68.7 (C-2, C-3, C-4, C-5), 50.3 (C-6), 40.0 (CH2CH2NHBoc), 39.5 
(CH2NHBoc), 33.9 (C-2Hex), 31.2 (C-4Hex), 28.3 (CMe3), 24.3 (C-3Hex), 22.2 (C-5Hex), 13.1 (C-
6Hex). ESI MS: m/z = 1517.4 [M + Na]
+
. Anal. Calcd for C70H118N12O19S2: calcd. C, 56.20; H, 
7.95; N, 11.24; O, 20.32; S, 4.29; found: C, 55.95; H, 7.84; N, 11.04; S, 11.04  
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[(6,6’-Di-4-(2-N’-(2-aminoehtyl)thioureido))methyl-1H-1,2,3-triazol-1-yl)-6,6’-dideoxy-
2,3,4,2’,3’,4’-hexa-O-hexanoyl]-,’-trehalose Dihydrochloride (10). Treatment of 48 (0.11 
g, 0.07 mmol) with TFA-DCM (2 mL) and freeze-drying from 0.1 N HCl solution afforded 10. 
Yield quant (0.10 g, 0.07 mmol). []D = +38.2 (c 1.0, MeOH); UV (MeOH): 243 nm (mM 16.9); 
IR: max = 2956, 2862, 1752, 1675 721 cm
-1
;
 1
H NMR (300 MHz, CD3OD): δ = 7.92 (s, 2 H, CH 
triazole), 5.44 (t, 2 H, J2,3 = J3,4 = 9.7 Hz, H-3), 5.08 (dd, 2 H,
 
J1,2 = 4.2 Hz, H-2), 4.95 (t, 2 H, H-
4), 4.82 (m, 4 H, H-4, H-1, CH2 triazole), 4.62 (dd, 2 H, J6a,6b = 14.0 Hz, J5,6a = 2.5 Hz, H-6ª), 
4.48 (dd, 2 H, J5,6b = 8.2 Hz, H-6b), 4.19 (ddd, 2 H, H-5), 3.91 (m, 4 H, CH2CH2NH2), 3.21 (dt, 4 
H, JH,H = 5.8 Hz, CH2NH2), 2.31 (m, 12 H, H-2Hex), 1.59 (m, 12 H, H-3Hex), 1.32 (m, 24 H, H-
4Hex, H-5Hex), 0.93 (m, 18 H, H-6Hex); 
13
C NMR (75.5 MHz, CD3OD): δ = 182.6 (CS), 176.0-
174.5 (CO), 146.1 (C-4 triazole), 125.6 (C-5 triazole), 92.4 (C-1), 71.4 (C-4), 70.6 (C-3), 70.4 
(C-5), 70.3 (C-2), 51.5 (C-6), 42.6 (CH2CH2NH2), 40.9 (CH2NH2), 40.2 (CH2-triazole), 35-34.8 
(C-2Hex), 32.5-32.4 (C-4Hex), 25.7-25.4 (C-3Hex), 23.2 (C-5Hex), 14.3 (C-6Hex); ESI MS: m/z = 
1357 [M + Cu]
+
; 711 [M + Cu]
2+ 
Anal. Calcd for C60H104N12O15S2: calcd. C, 52.66; H, 7.66; N, 
12.28; S, 4.69; found: C, 52.71; H, 7.50; N, 12.55, 4.69. 
6,6’[-4-(2,2-Bis-tert-butoxycarbonylamino)ethylaminomethyl)-1H-1,2,3-triazol-1-yl)-6-
deoxy-2,3-di-O-hexanoyl]-,’-trehalose (49). To a solution of 44 (0.31 g, 0.31 mmol) and 29 
(0.24 g, 0.73 mmol) in H2O-
t
BuOH 9:1(15 mL), the Cu-supported catalyst Si-BPA·Cu
+ 
(0.02 g) 
was added and the reaction mixture was refluxed for 36 h at 85 ºC. The catalyst was filtered and 
the solvent was removed. The residue was purified by column chromatography (2:1 → 3:1 
EtOAc-cyclohexane). Yield 91% (0.54 g, 0.29 mmol). Rf = 0.36 (3:1 EtOAc-cyclohexane). []D 
= +57.0 (c 1.0, DCM ); IR: max = 2958, 2359, 2341, 1751, 1700 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3): δ = 7.57 (s, 2 H, =CH), 5.47 (t, 2 H, J2,3 = J3,4 = 9.8 Hz , H-3), 5.20 (bs, 4 H, NHBoc), 
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4.93 (dd, 2 H,
 
J1,2 = 3.8 Hz, H-2), 4.86 (t, 2 H, J4,5 = 10.0 Hz, H-4), 4.77 (d, 2 H, H-1), 4.46 (bd, 
2 H, J6a,6b = 14.0 Hz, H-6ª), 4.25 (dd, 2 H, J5,6b = 8.7 Hz, H-6b), 4.12 (m, 2 H, H-5), 3.83 (bs, 4 
H, CH2 triazole), 3.19 (bd, 8 H, 
3
JH,H = 6.0 Hz, CH2NHBoc), 2.55 (t, 8 H, JH,H = 6.0 Hz, 
CH2CH2NHBoc), 2.27 (m, 12 H, H-2Hex), 1.58 (s, 36 H, CMe3), 1.44 (m, 12 H, H-3Hex), 1.30 (m, 
24 H, H-4Hex, H-5Hex), 0.89 (m, 18 H, H-6Hex); 
13
C NMR (75.5 MHz, CDCl3): δ = 174.2-173.0 
(CO ester), 156.2 (CO carbamate), 143.9 (C-4 triazole), 124.3 (C-5 triazole), 91.4 (C-1), 79.1  
(CMe3), 69.5 (C-4), 69.3 (C-3), 69.2 (C-5), 68.8 (C-2), 53.1 (CH2CH2NHBoc), 50.6 (C-6), 48.0 
(CH2-triazole), 38.4 (CH2NHBoc), 34.1 (C-2Hex), 31.7 (C-4Hex), 28.5 (CMe3), 24.6 (C-3Hex), 22.6 
(C-5Hex), 13.8 (C-6Hex); ESI MS: m/z = 1686.6 [M + Na]
+ 
. Anal. Calcd for C82H142N12O23: calcd. 
C, 59.18; H, 8.60; N, 10.10; found: C, 59.20; H, 8.51; N, 10.15. 
6,6’[4-(2,2-Diaminoethylaminomethyl)-1H-1,2,3-triazol-1-yl)-6,6’-dideoxy-2,3,4,2’,3’,4’-tri-
O-hexanoyl]-,’-trehalose Tetrahydrochloride (11). Treatment of 49 (0.56 g, 0.34 mmol) 
with TFA-DCM 1:1 (6 mL) and freeze-drying from 0.1 N HCl solution afforded 11. Yield quant. 
(0.48 g, 0.33 mmol). []D = +22.1 (c 1.0, MeOH); IR: max = 2956, 2356, 1753, 1676, 721 cm
-1
;
 
1
H NMR (300 MHz, CD3OD): δ = 8.33 (s, 2 H, CH triazole), 5.51 (t, 2 H, J3,4 = J2,3 = 9.7 Hz, H-
3), 5.08 (dd, 2 H,
 
J1,2 = 3.9 Hz, H-2), 5.01 (t, 2 H, J4,5 = 9.7 Hz, H-4), 4.95 (d, 2 H, H-1), 4.65 
(dd, 2 H, J5,6a= 3.0 Hz, J6a,6b = 14.5 Hz, H-6a), 4.56 (dd, 2 H, J5,6b = 8.1 Hz, H-6b), 4.28 (bs, 4 H, 
CH2 triazole), 4.18 (ddd, 2 H, H-5), 3.41 (bt, 8 H, 
3
JH,H = 
3
JH,NH  = 6.0 Hz, CH2NH2), 3.22 (bt, 8 
H, CH2CH2NH2), 2.31 (m, 12 H, H-2Hex), 1.59 (m, 12 H, H-3Hex), 1.33 (m, 24 H, H-4Hex, H-5Hex), 
0.93 (m, 18 H, H-6Hex); 
13
C NMR (75.5 MHz, CD3OD): δ = 174.2-173.2 (CO), 141.1 (C-4 
triazole), 128.8 (C-5 triazole), 91.9 (C-1), 71.0 (C-4), 70.6 (C-3), 70.5 (C-5), 70.4 (C-2), 51.8 (C-
6), 51.6 (CH2CH2NH2), 47.9 (CH2-triazole), 37.2 (CH2NH2), 35.1-34.8 (C-2Hex), 32.5-32.4 (C-
4Hex), 25.6-25.5 (C-3Hex), 23.4 (C-5Hex), 14.3 (C-6Hex); ESI MS: m/z = 1263.5 [M]
+
; 632.0 [M]
2+
.
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Anal. Calcd for C62H114N12O15: calcd. C, 52.83; H, 8.15; N, 11.93; found: C, 52.87; H, 8.04; N, 
11.74. 
Determination of CMC via Pyrene Fluorescence Measurements. In order to assess the 
amphiphilicity, the critical micelle concentrations (CMC) of all derivatives have been determined 
using an established fluorescence technique based on pyrene.
46
 This extremely hydrophobic dye 
is preferentially incorporated in the interior of micelles. The onset of micelle formation can be 
observed in a shift of the fluorescence excitation spectra of the samples at an emission 
wavelength of 372 nm. In the concentration range of aqueous micellar solutions, a shift of 
the excitation band in the 335 nm region toward higher wavelengths confirms the incorporation 
of pyrene in the hydrophobic interior of micelles. The ratio of the fluorescence intensities at 339 
and 335 nm was used to quantify the shift of the broad excitation band. The critical micelle 
concentrations were determined from the crossover point in the low concentration range. 
Fluorescence spectra were recorded with an F-2500 Hitachi spectrofluorophotometer and 
conventional 1-cm quartz cuvettes at 37 ± 0.1 ºC, using 2.5 mm excitation and emission slits. 
Synthesis of Dodecanethiol Coated Gold Nanoparticles (DDT-Au NPs). A solution of 
tetrachloroaurate acid in milli-Q water (25 mL, 0.03 M) was mixed with a solution of 
tetraoctylammonium bromide in toluene (80 mL, 0.05 M). The two phases mixture was 
vigorously stirred until all the tetrachloroaurate was transferred into the organic layer, and the 
aqueous layer was discarded. To the solution was added dropwise a NaBH4 aqueous solution (25 
mL, 0.35 M) for 1 minute, then the mixture was stirred for 1 h. The biphasic system was washed 
with 0.01 M HCl (1 x 25 mL), 0.01 M NaOH (1 x 25 mL) and H2O milli-Q (3 x 25 mL). 
Aqueous layers were discarded and the organic phase was stirred overnight at rt. Dodecanethiol 
(10 mL, 42 mmol) was added and the mixture was refluxed for 3 h. The system was cooled to rt 
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and spin-dried at 2000 rpm for 10 min. The supernatant was recovered, and MeOH was added to 
reach 1:1 mixture to precipitate the NPs and eliminate the excess of dodecanethiol, and the 
system was spin-dried for 10 min at 2000 rpm. Then supernatant was discarded and the 
precipitate was suspended in 1 mL of CHCl3. 
The final concentration of DDT-Au NPs was determined by UV spectrometry. A small aliquot of 
NPs was 1000-fold diluted and absorbance was measured using a ε = 8.63 · 106 M-1cm-1.50  
Coating of DDT-Au_NPs with Compound 11. To a solution of DDT-Au NP (120 L) in 
CHCl3 (30 mL) was added a solution of compound 11 in MeOH (1 mL, 2 mM). The mixture was 
concentrated and milli-Q water (300 L) was added before 1 min sonication. The dark red 
solution was spin-dried in a ultrafiltration device with a polyethersulfone membrane (Corning® 
Spin-X® UF) for 5 min at 6000 rpm. The precipitate was recovered by addition of milli-Q water 
(500 L). Final concentration was determined measuring the absorbance at 450 nm using an ε = 
3.07· 10
7 
M
-1
cm
-1
. 
Biological Assays 
Reagents and Cell Cultures. Expression plasmid for mouse MD-2 was a gift from Dr. Y. Nagai 
(University of Tokyo, Japan). Expression plasmid for mouse TLR4 was purchased from 
InvivoGen (CA, USA). Expression plasmids containing sequences of human TLR4 and MD-2 as 
well as the pELAM-1 firefly luciferase plasmid were a gift from Dr. C. Kirschning (Technical 
University of Munich, Germany). The Renilla luciferase phRL-TK plasmid was purchased from 
Promega (WI, USA). 
The human embryonic kidney (HEK) 293 cells were provided by Dr. J. Chow (Eisai Research 
Institute, Andover, USA). HEK293 cells were grown in DMEM supplemented with 10 % FBS. 
Compounds were dissolved in 100% DMSO to provide 4 mM stock solutions; further working 
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dilutions were prepared immediately before stimulation with cell medium (DMEM supplemented 
with 10 % FBS). 
Cell Activation Assay – NF-B-Luciferase Reporter Assay. HEK 293 cells were seeded in 96-
well Costar plates (Corning, NY, USA) at 1.6∙104 cells/well and incubated overnight in a 
humidified atmosphere (5 % CO2) at 37 °C. The next day, when cells were 40-60 % confluent, 
they were co-transfected with MD-2 (10 ng), NF-B-dependent luciferase (70 ng) and 
constitutive Renilla (15 ng) reporter plasmids and TLR4 plasmid (1 ng) using PEI (7.5 molar 
polyethylenimine pH 7.5, Polysciences) transfection reagent. Cells were stimulated 4 hours after 
transfection with the synthetic compounds, then1 h later with LPS (5 nM) that was extensively 
vortexed immediately prior to stimulation. Cells were lysed after 16 hours of stimulation in 1x 
reporter assay lysis buffer (Promega, USA) and analyzed for reporter gene activities using a 
dual-luciferase reporter assay system. Relative luciferase activity (RLA) was calculated by 
normalizing each sample’s firefly luciferase activity for constitutive Renilla activity measured 
within the same sample. When plotting the data the value of the wild type MD-2·TLR4 sample 
stimulated with LPS was normalized to 100 and other values were adjusted accordingly. 
HEK-Blue
TM
 Assay. HEK-Blue-TLR4 cells (InvivoGen) were cultured according to 
manufacturer’s instructions. Briefly, cells were cultured in DMEM high glucose medium 
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 1x Normocin (InvivoGen), 
1x HEK-Blue Selection (InvivoGen). Cells were detached by the use of a cell scraper and the 
cell concentration was estimated by using Trypan Blue (Sigma Aldrich). The cells were diluted 
in DMEM high glucose medium supplemented as described before and seeded in multiwell plate 
at a density of 2x10
4
 cells/well in 200 µL. After overnight incubation (37°C, 5% CO2, 95% 
humidity), supernatant was removed, cell monolayers were washed with warm PBS without Ca
2+
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and Mg
2+
 and treated with increasing concentrations of compounds dissolved in DMSO-ethanol 
(1:1). After 30 minutes, the cells were stimulated with 10 nM LPS from E. coli O55:B5 (Sigma 
Aldrich) and incubated overnight at 37°C, 5% CO2 and 95% humidity. As a control, the cells 
were treated with or without LPS (10 nM) alone. Then, the supernatants were collected and 50 
µL of each sample was added to 100 µL PBS, pH 8, 0.84 mM para-Nitrophenylphosphate 
(pNPP) for a final concentration of 0.8 mM pNPP. Plates were incubated for 2-4 h in the dark at 
rt and then the plate reading was assessed by using a spectrophotometer at 405 nm (LT 4000, 
Labtech).  The results were normalized with positive control (LPS alone) and expressed as the 
mean of percentage ± SD of at least three independent experiments.  
MTT Cell Viability Assay. HEK-Blue cells were seeded in 100 μL DMEM without Phenol Red 
at a density of 2x10
4
 cells per well. After overnight incubation, 10 µL compounds were added 
and the plates were incubated overnight at 37 °C, 5% CO2, 95% humidity. DMSO and PBS were 
included as control. Then 10 μl of MTT solution (5 mg/mL in PBS) were added to each well. 
After 3 h incubation (37 °C, 5% CO2, 95% humidity), HCl 0.1 N in isopropanol was added (100 
μl/well) to dissolve formazan crystals. Formazan concentration in the wells was determined 
measuring the absorbance at 570 nm (LT 4000, Labtech).  The results were normalized with 
untreated control (PBS) and expressed as the mean of percentage ± SD of three independent 
experiments. 
In vivo Endotoxin Inhibition. C57BL/6J mice (11-13 weeks old) were randomly assigned into 
groups and injected intraperitoneally with vehicle control (5% DMSO in PBS) (groups none and 
LPS only) or the inhibitory compound (2x10
-7
 mol compound/mouse for compounds 5-11, all in 
5% DMSO solution). One hour later the mice were injected intraperitoneally with vehicle control 
(PBS) (group none) or with LPS from E. coli 055:B5 (1x10
-9
 mol / mouse ≈ 10 µg LPS / mouse). 
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Three hours later the blood was collected. Serum was tested with the mouse TNF-α ELISA kit 
("ReadySetGo", eBioscience) to determine the levels of mouse TNF-α. The experiment was 
performed according to the manufacturer's instructions.   
Supporting Information. Activity of compounds 5, 9, 10 on bone marrow-derived murine 
macrophages (BMDM); MTT cell toxicity tests for synthetic molecules. This material is 
available free of charge via the Internet at http://pubs.acs.org. 
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BMDM, bone marrow derived machophages; CNS, central nervous system; DC, dendritic cell; 
DCC, dicyclohexylcarbodiimide; DMEM, Dulbecco's modiﬁed Eagle's medium; DMAP, 4-
dimethylaminopyridine; DMSO, dimethysulfoxide;  HEK, human embryonic kidney; PTSA, p-
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toluenesulfonic acid; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test; 
NF-B, nuclear factor kappa-light-chain-enhancer of activated B cells; TPP, triphenylphosphine; 
TRAM, TRIF-related adaptor molecule; TRIF, TIR-domain-containing adapter-inducing 
interferon-β. 
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